

Table of Contents

The Tools	3
Tools – SET A	4
TOOL AA - Stakeholder ID and Analysis TOOL A1 - Engagement Log TOOL A2 - Compilation of Clinical Trial Data TOOL A3 - Inventory of CSE alongside GPP Guidelines	4 9 12 16
Tools – SET B	23
TOOL B1 - Community Stakeholder Interview TOOL B2 - Community Advisory Group Member or Community Representative Interv TOOL B3 - Broader Stakeholder Interview Tools - SET C	23 riew 30 38 45
TOOL C1 - Trial Participant Interview TOOL C2 - Prospective Trial Participant Interview Tools - SET D	45 51 56
TOOL D1 - Self Assessment - For Community Engagement Manager or CLO TOOL D2 - Self Assessment - For Senior Researcher or Principal Investigator	56 64

The Tools

- This document presents the tools that are currently uploaded onto the server.
- This document serves as a hard copy of the tools in printable format.
- The tools are divided into 4 sets A, B, C, D. The tools are used at different intervals, the specifics of which would be determined by each individual CSE's M&E Program.
- The tools are presented in this document however their format is slightly different on the database where questions are presented 2-3 per page. In addition the post coded options are presented in a in a more user friendly manner on the database. This pack however, can be useful if you need to reproduce paper copies of the tools.




Figure 1: Tool Matrix

Tools - SET AA

Stakeholder ID and Analysis

When to complete

- Daily or equivalent.
- To be completed whenever a new stakeholder is engaged.
- Updated automatically via A1.
- Revisited to rate power and engagement intermittently.

Number to complete

- There is no defined sample size.
- The more stakeholders you consult with the more information you will have in your database to use for effective planning or M&E.

Estimated Time

• 15 minutes the database.

TOOL AA – Stakeholder ID and Analysis

AA-1.1 STUDY SITE							
AA-1.2 REFERENCE							
(always used for this SH) AA-1.3 STAKEHOLDER NAME							
AA-1.4 STAKEHOLDER TYPE							
	Comm	nunity SH Broader SH	National SH	International SH			
AA 1.5 TYPE OF STAKEHOLDER	THE TINITIVITAL RESIDENT			COMMUNITY HEA	LTH WORKER		
Select one only	ADVO	CATE or ACTIVIST		LOCAL BUSINESS	OWNERS		
	CBO S	STAFF		LEGAL EXPERT			
	SCHO	OL TEACHER		MEDIA /JOURNAL	ISTS		
	YOUTH WORKER			LOCAL POLICY MAKERS			
	HEALTH FACILITY STAFF			LOCAL BUSINESS			
	TRADI	ITIONAL HEALER		NGO STAFF			
	LOCAL	L FAITH BASED LEADER		INTERNATIONAL A	ADVISORY BOARD)	
		L LEADERSHIP - GOVT OR ELECT	ΓED	SPONSOR/COORD	DINATOR		
	LOCA	L LEADERSHIP - TRADITIONAL		DONOR			
				OTHER Specify in	detail:		
AA-1.6.1 - AA-1.6.4	Dat	te	Link to Engager	nent Log - date	Link to a key i	nforma	nt interview
Dates of Engagement List all dates when this stakeholder was	as dd/	/mm/yyyy					
engaged in some way	dd/	/mm/yyyy					
Automatic update from A1	dd/	/mm/yyyy					
AA 4 = WUW ABE VOU ENGAGING WU		TALKELIOL DED					
AA-1.7 WHY ARE YOU ENGAGING WITH THIS STAKEHOLDER Narrate in detail why you are engaging with this stakeholder —i) why are you engaging this person/group i) what can the stakeholder/group benefit from engagement and how can the trial benefit from his or her engagement. Narrative							
AA-1.8 Is this stakeholder supportive	or resistant	nt to engagement? Only choose of	ne.	RESISTANT/CONFLIC	т		
COLLABORATIVE/SUPPORTIVE							
				COLLABORATIVE/SUF	PPORTIVE .		
AA - 1.9 Personally rate the power where he or she has a sphere of in		cholder or stakeholders holds in		COLLABORATIVE/SUF	PPORTIVE High	Med	Low/None
	fluence. stakeholder	r have knowledge or skills relating	n the area			Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS – does this s	fluence. stakeholder amics, educ	r have knowledge or skills relating cation, etc. of relevance to the tri	n the area I to the disease or al locally or more t			Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be rea	fluence. stakeholder amics, educ ARTICULA ached to op	r have knowledge or skills relating teation, etc. of relevance to the tri NR GROUPS – does this stakehold pen lines of communication from	n the area I to the disease or al locally or more in the have access and to the trial?			Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS – does this s its management or to community dyna COMMUNICATION CONTROL WITH P	fluence. stakeholder amics, educe ARTICULA ached to op this stakehol	r have knowledge or skills relating teation, etc. of relevance to the tri NR GROUPS – does this stakehold pen lines of communication from	n the area I to the disease or al locally or more in the have access and to the trial?			Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be rea AUTHORITY — REGULATORY — does to	stakeholder amics, educ ARTICULAI ached to op this stakeho broadly?	r have knowledge or skills relating teation, etc. of relevance to the trick that the stakehold pen lines of communication from tolder hold influence or power over a status in his sphere or in his communication.	n the area If to the disease or al locally or more is the following the second of the trial? If authorization or the community or in the second of the trial?	broadly?		Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be red AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or h SOCIAL TIES/CONNECTIONS — does	stakeholder amics, educ ARTICULAI ached to op this stakeho broadly? holder hold aer to open this stakeho	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the state	n the area In to the disease or al locally or more if the have access and to the trial? In authorization or community or in the into the trial? In the trial?	broadly? e nity		Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be red AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or he	stakeholder amics, educe character to open this stakeholder hold are to open this stakeholder to open this stakeholder to open this stakeholder hold are to open this stakeholder holder hold are to open this stakeholder holder hol	r have knowledge or skills relating teation, etc. of relevance to the trick that the stakehold pen lines of communication from tolder hold influence or power over a status in his sphere or in his continues of communication from and tholder hold social ties or connection to open lines of communication	n the area In to the disease or al locally or more in the have access and to the trial? In authorization or community or in the into the trial? In the trial? In the trial on the trial on the trial on the trial?	broadly? e nity ial?		Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be rea AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or h SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables	stakeholder amics, educe the stakeholder hold ached to open this stakeholder to open this stakeholder to open this stakeholder to broadly?	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the trick that the state of	n the area In to the disease or al locally or more in the have access and to the trial? For authorization or community or in the final to the trial? For sin the community or in the trial to the trial?	broadly? e nity ial? ore broadly?		Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be rea AUTHORITY — REGULATORY — does it regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or h SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this	stakeholder amics, educe character amics, edu	r have knowledge or skills relating teation, etc. of relevance to the tricks of the tr	n the area In to the disease or al locally or more if the have access and to the trial? In authorization or In authorization or In authorization or In the disease or In authorization or In authorization or In the community or in the district of the trial? In all or components or In the area	proadly? e nity ial? ore broadly? f the trial?		Med	Low/None
where he or she has a sphere of in. KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be rea AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or h SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this In your opinion does this stakeholder have	takeholder amics, educe this stakeholder holder holder to open this stakeholder to open this stakeholder a PERCEI e a PERCEI	r have knowledge or skills relating teation, etc. of relevance to the tricks of the tr	In the area In to the disease or all locally or more in the access and to the trial? In authorization or authorization or authorization or authorization or in the first to the trial? In all or components or all or compo	proadly? e nity ial? ore broadly? f the trial? mponents of the trial.	High	Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be read AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or him SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this In your opinion does this stakeholder have In your opinion does this stakeholder have AA-1.10 Select the extent of the statement of	this stakeholder to open this stakeholder hold to open this stakeholder hold the to open this stakeholder to open the a PERCEI to a PERCEI takeholders ovided with	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the state	In the area In to the disease or all locally or more in the following and to the trial? In authorization or authorization or authorization or authorization or authorization or and to the trial? In a to the trial? In a to the trial? In a to the trial or components or all or components or all or components or all or the trial or components or all the trial or components o	ore broadly? fithe trial? mponents of the trial. he trial or components of the trial.	High	Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be read AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or him SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this In your opinion does this stakeholder have In your opinion does this stakeholder have AA-1.10 Select the extent of the statement of	takeholder amics, educe this stakeholder holder holder to open this stakeholder to open this stakeholder appendix akeholder appendix appendix approach	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the trick that the state of the trick that the state of the state o	In the area In to the disease or all locally or more in the access and to the trial? In authorization or authorization or community or in the district to the trial? In and to the trial? In and to the trial or community or in the community or in the district the trial or components or the district this point in time assues as they arises.	ore broadly? fithe trial? mponents of the trial. he trial or components of the trial.	High	Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be read AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or him SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this In your opinion does this stakeholder hav In your opinion does this stakeholder hav AA-1.10 Select the extent of the statistical information of the statistical problem of	this stakeholder to open the a PERCEI of a PERCEI ovided with y approach irectly and a preconsiste	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the trick that the state of the trick that the state of the state o	a to the disease or all locally or more in the area and to the trial? The authorization or and to the trial? The authorization or and to the trial or components or all or components or	ore broadly? fithe trial? mponents of the trial. he trial or components of the trial.	High	Med	Low/None
where he or she has a sphere of in KNOWLEDGE & SKILLS — does this s its management or to community dyna COMMUNICATION CONTROL WITH P to important groups who should be read AUTHORITY — REGULATORY — does to regulations in the community or more PRESTIGE/STATUS — does this staked broader arena which enables him or him SOCIAL TIES/CONNECTIONS — does or in the broader arena which enables ECONOMIC — FINANCIAL — does this In your opinion does this stakeholder have In your opinion does this stakeholder have AA-1.10 Select the extent of the statement of	this stakeholder to open this stakeholder to open this stakeholder to open this stakeholder to open this stakeholder to a PERCEI to a PERC	r have knowledge or skills relating teation, etc. of relevance to the trick that the state of the trick that the state of the trick that the state of the state o	a to the disease or all locally or more in the area and to the trial? The authorization or and to the trial? The authorization or and to the trial or components or all or components or	oroadly? ore broadly? f the trial? mponents of the trial. he trial or components of the trial. INFORMED CONSULTED	High	Med	Low/None

AA - 1.11 Select the nature of this stakeholders' participation.	UNCONCERNED/PASSIVE	
	CONCERNED/NOT ACTIVE	
	INFLUENTIAL/NOT ACTIVE	
	ACTIVE/NOT INFLUENTIAL	
	INFLUENTIAL/ACTIVE	

Tools - SET A1

Engagement Log

When to complete

- Daily or the equivalent.
- To be completed as soon after any of the following:
 - CSE Consultation in person-email or on the phone.
 - CAB/Advisory Mechanism planning or implementation (meeting or event).
 - Media consultation planning or implementation or exchange in person or in writing.
 - Outreach planning or implementation.

Number to complete

- There is no defined sample size.
- As many entries as needed each day this data is entered directly into the database.
- The log is intended to capture all your CSE activities in brief from planning through to implementation.
- The more committed you are to logging your CSE activities, the richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Estimated Time

• 5 minutes per log.

TOOL A1 – COMMUNITY ENGAGEMENT LOG

Instructions: This form is to be completed as soon as CSE takes place - relating to consultations, CAB/CAG/CR; outreach and media.

	KINDS OF COMMUNITY ENGAGEMENT – RECORDED IN TOOL A1
CONSULTATION – with individuals and small groups	These are conversations and meetings and check ins you may carry out with specific stakeholders to address a wide variety of issues.
	 Consultation may include any: Meetings with community stakeholders. Discussions around community entry, mobilization, sensitization and education, participant recruitment in relation to community entry, engagement, updates and feedback during and after the trial. May also include phone calls with stakeholders or a visit to the clinic to 'pop in' to touch base or update – consultations can be scheduled or unscheduled with any of the relevant community stakeholders. Written communication if introductory or of significance in the form of 'consultation' can also be included.
COMMUNITY ADVISORY GROUP/BOARD/FORUM	These include any / all activities related to the CAB. For example, meetings to plan a CAB meeting, recruiting members, training of members and any CAB initiated outreach activities.
OUTREACH — to large groups	These include outreach related to any health calendar events, screening days, community meetings, dialogues, barazas, theatre or music events, education sessions in institutions (schools, clinics, and universities), training of peer educators. Outreach must involve activities that directly or indirectly relate to the trial and its relevance to the community where you are doing the outreach. This may also include results dissemination.
MEDIA	These include radio, flyers, posters, newsprint, television, press releases and social media of any kind.

# A1 A1.1 NAME OF PERSON WHO DID THE ENGAGEMENT:	NGAGEMENT:	TITLE/POSITION OF PERSON WHO DID THE ENGAGEMENT:	THE ENGAGEMENT:
1. DAY/MONTH AND YEAR	6. FORM OF ENGAGEMENT CONSULTATION CONSULTATION EMAIL ONE TO ONE MEETING (NOT CAB) ROUTINE/ SCHEDULED MEETING (NOT CAB) NOSCHEDULED OR EMERGENCY GROUP MEETING (NOT CAB) SMALL SUBCOMMITTEE MEETING (NOT CAB) OTHER	7. ATTENDANCE OR REACH NOTE: Enter the exact number of people in attendance or reached though consultation or outreach. If this is not possible, then enter the approximate number in attendance at the event. In the case of media, you can indicate the number you expect will be reached through your media avenues. EXACT - ENTER NUMBER OF PEOPLE IN ATTENDANCE AT MEETING OR OUTREACH	9. PLACE – LOCATION /GPS COORDINATES MY OFFICE PHONE CALL RESEARCH CLINIC DOH/MOH HEALTH FACILITY HOME VISIT IN COMMUNITY
2. TYPE OF COMMUNITY ENGAGEMENT Read definitions and choose ONE CONSULTATION COMMUNITY ADVISORY GROUP/BOARD/FORUM Name of CAB: OUTREACH MEDIA 3. TRACKING NUMBER A unique consecutive number (generated by software).	CAB ROUTINE/ SCHEDULED CAB MEETING NUSCHEDULED OR EMERGENCY CAB MEETING EXECUTIVE COMMITTEE CAB MEETING OTHER GLOBAL HEALTH EVENT HEALTH OF RESEARCH EDUCATION HEALTH SCREENING GENERAL COMMUNITY MEETING PEER EDUCATION	OR APPROXIMATE - IF EXACT NUMBER NOT KNOWN- APPROXIMATE NUMBER OF PEOPLE ATTENDING OR BEING REACHED OR EXPECTED - IF NUMBER NOT APPROXIMATED- ENTER NUMBER OF PEOPLE EXPECTED TO BE REACHED BY THE ENGAGEMENT	□ CONFERENCE□ WORKSHOP□ SHOPPING AREA□ SOCIAL CLUBS□ LEARNING INSTITUTION□ OTHER
4. FOCUS OF ENGAGEMENT (can choose many) Planning Training Implementation Communication Follow up 5. TIME SPENT ON THIS SPECIFIC ENGAGEMENT ACTIVITY BEING LOGGED Start: Finish:	HEALTH WORKER TRAINING THEATRE/MUSIC EVENT SPORT EVENT SPORT EVENT OTHER LOCAL RADIO ADVERTISEMENT LOCAL RADIO INTERVIEW REGIONAL/NATIONAL RADIO ADVERTISEMENT REGIONAL/NATIONAL RADIO ADVERTISEMENT REGIONAL/NATIONAL REGIONAL/NATIONAL REGIONAL/NATIONAL REDIO INTERVIEW TELEVISION ADVERT TELEVISION INTERVIEW LOCAL NEWSPRINT LOCAL PRESS RELEASE NATIONAL NEWSPRINT NATIONAL PRESS RELEASE SOCIAL MEDIA UPDATE INTERNET PLATFORM	8. TRAINING DID ANY TRAINING TAKES PLACE AT MEETING:	
 	☐ POSTERS ☐ FLYERS ☐ BILLBOARDS ☐ OTHERSPECIFY		

	ļ	
10. SPECIFICS OF MEDIA ENGAGEMENT	11. PURPOSE OF COMMUNITY ENGAGEMENT/ISSUES ADDRESSED	12. COMMUNITY STAKEHOLDERS INVOLVED/REACHED/TARGETED
Can only be answered It "IMEDIA" was selected for NUMBER 2	Choose muitiple ADHFRENCE ISSUES	Choose multiple ADVOCATES & ACTIVISTS OTHER
VAME OF RADIO STATIONS USED FOR MEDIA CAMPAIGN OR RELEASE attach sound clip if possible or text)	CAB MANAGEMENT COMMINICATION PLAN	SOCIETY ORG
Account of the second of the s	COMMUNITY ENTRY/INTRO	COMMUNITY OUTREACH HEALTHCARE WORKERS
	DOCUMENTATION OF PRACTICES & LESSONS LEARNED	DEPARTMENT OF HEALTH LOCAL/ZONAL
	DOST TRIAL ACCESS TO CARE	U DEPARTMENT OF HEALTH NATIONAL
NAME OF TV STATION FOR MEDIA CAMPAIGN OR RELEASE	FOLLOW OF ISSUES FORMATIVE WORK	☐ DISABLED PEOPLE
(attach clip if possible or text)	☐ INFORMED CONSENT REVIEW/DISCUSSION/TRAINING	☐ KEY (MARGINALIZED - AT RISK) POPULATIONS
	MOBILIZATION/SENSITIZATION/EDUCATION AT DIFFERENT SITES	CENTRAL PUBLIC
	PLANNING FOR EVENTS	If you can specify -
VAME OF NEWSPAPER FOR MEDIA CAMPAIGN OR RELEASE	POST I RIAL ACCESS TO CARE	GENERAL PUBLIC - CHILDBEARING AGE — FEMALE GENERAL PUBLIC - CHILDBEARING AGE — MALE
make sure to attach newspaper article)	☐ PROTOCOL REVIEW	GENERAL PUBLIC - PREGNANT WOMEN
	POST TRIAL ACCESS TO CARE	GENERAL PUBLIC - ELDERLY - FEMALE
	NECHOLINIEN CA 	GENERAL FUBLIC - ELUENLI - INALE
TO STITLE TO STAND TO STAND STANDS OF STANDS	ERCRUTMENT CAB	GENERAL PUBLIC - YOUTH/YOUNG ADULTS - FEMALE -
VAINTE OF SOCIAL IMEDIA FOR MEDIA CAMIPAIGIN OR RELEASE OR POSTINGS	RESOURCE IDENTIFICATION	IN EDUCATION
or in communication) (make sure to attach screen shots of any comments or communication)	RESULTS DISSEMINATION DETENTION SCIENCE DETENTION SCIENCE	GENERAL PUBLIC - YOUTH/YOUNG ADULTS - MALE -
	Releanton Isoues	IN EDUCATION GENERAL PUBLIC - YOUTH/YOUNG ADULTS - FEMALE -
	SITE SELECTION	OUT OF EDUCATION
	STAKEHOLDER ADVISORY PLAN	GENERAL PUBLIC - YOUTH/YOUNG ADULTS - MALE -
NAME OF POSTEB	STAKEHOLDER EDUCATION PLAN	OUT OF EDUCATION
make sure to attach copy)	STUDY BRIEFING/I RAINING	FALIH BASED LEADERS
	TRAINING IN COMMUNITIES	☐ FRONTLINE HEALTH FACILITY STAFF
NAME OF FLYEB	TRAINING OF CAB	☐ HOME BASED CARERS
make sure to attach copy)	UPDATES/FEEDBACK RELATED TO EVENTS (NOT STUDY UPDATES)	COCAL GOVERNMENT LEADERSHIP
		☐ NON GOVERNMENT/COMMUNITY BASED/CIVIL SOCIETY BASED ☐
OTHER(specify and attach)		ORGANISATIONS
		☐ PROSPECTIVE PARTICIPANTS
		EGION/NATIONAL POLITICAL LEADERS
		REGION/NATIONAL TRADITIONAL LEADERS
		KESIDENTS (UTSPECIFIED) IN THE CALCHIMENT AREA SCIENTIFIC COMMITTEE MEMBERS
		SPONSOR/DONOR
		IEACHERS/LECIUMERS/PROFESSORSTRADITIONAL HEALERS
		☐ TRIAL PARTICIPANTS

15. NEXT STEPS: 1)	4)	16. FURTHER COMMENTS				
13. OUTCOME NARRATIVE PLEASE DESCRIBE IF THIS COMMUNITY ENGAGEMENT EVENT WAS USEFUL OR NOT USEFUL AND WHY. DID IT ACHIEVE WHAT WAS EXPECTED? DO YOU KNOW IF IT ACHIEVED ANYTHING? ANY FOLLOW UP?		14. OUTCOME SUMMARY THIS COMMUNITY ENGAGEMENT EVENT WAS: <i>Choose one from each category</i>	□ USEFUL □ NOT USEFUL	□ EFFECTIVE □ NOT EFFECTIVE	TIME CONSUMING NOT TIME CONSUMING	☐ SUSTAINABLE ☐ NOT SUSTAINABLE

Tools - SET A2

Compilation of Clinical Trial Data

When to complete

- Monthly.
- This form is to be compiled monthly at the end of each month and the information should be extracted from clinical trial recruitment and retention data.

Number to complete

- There is no defined sample size.
- The more committed you are to extracting the clinical data and developing your own system to ensure it is done efficiently, means that you will have a complete data set which will have more value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Estimated Time

• 15 minutes to 30 minutes – including planning access to data with your data management team.

TOOL A2 – Clinical Trial Data Extraction Form

Instructions: This form is to be compiled monthly - at the end of each month and the information should be extracted from clinical trial recruitment and retention data.

SECTION 1: GENERA	AL INFORMATION	
A2 - 1.0	NAME OF TRIAL	
A2 - 1.1	NAME OF SITE – STUDY LOCATION	
A2 - 1.2	PROTOCOL/SUB-STUDY NUMBER	
A2 - 1.3	MONTH BEING COMPILED (all data will be collected about this month) Choose one:	JANUARY FEBRUARY MARCH APRIL MAY JUNE JULY AUGUST SEPTEMBER OCTOBER NOVEMBER DECEMBER
A2 - 1.4	YEAR	20
A2 - 1.5	YEAR OF TRIAL Choose one	YEAR ONE OF TRIAL YEAR TWO OF TRIAL YEAR THREE OF TRIAL YEAR FOUR OF TRIAL
A2 - 1.6	NAME OF PERSON COMPILING	

SECTION 2: CLINICAL TRIAL STAGES FOR THE MONTH					
Check each stage that has occurred during the month. You may choose multiple. Some of these stages may take place abroad and you may or may not have been involved. However, if you know that these stages took place during the MONTH that you are compiling, and then focus on that stage.					
Section 3 applies only to REC – For recruiting, RET-ADH – Re	tention and Adherence and PFU – Participant follow up				
F - Formative work PD - Protocol review/development PR - Protocol review TS - Training staff in protocol use SS - Site selection CE - Community Entry SA - Site Activation REC - For recruiting	RET-ADH – Retention and Adherence PFU – Participant follow up END REC – End of recruitment END DU – End of study drug use END TR – End of Trial DA – Data Analysis CT – POST TRIAL ACCESS TO CARE/ Compassionate Treatment DIS PRELIM – dissemination of preliminary results				
L REC - For recruiting	DIS FINAL – dissemination of final results				

SECTION 3: CLINICA	AL TRIAL RECORDS	
A2 - 1.6	Number of participants you are expected to enrol this month (this is the monthly target).	
A2 - 1.7	Number of potential participants screened this month.	
A2 - 1.8	Number of participants actually enrolled into the trial this month (this is not cumulative).	
A2 - 1.8 a	Zone/Region/Number of potential participants screened this month from this zone/region/ward (ADD up to 12).	
A2 - 1.8 b	Recruiting Facility Number of potential participants screened this month for the trial at this facility (ADD up to 12 recruiting facilities).	
A2 - 1.9	Success of enrolment for this month - % of expected participants actually enrolled (an indication of how well targets are being met).	
A2 - 1.9 a	Outcome of screening - % of cumulative Number of potential participants screened by the trial this month divided by the Number of participants actually enrolled on the trial this month.	
A2 - 1.10	Cumulative Number of expected enrolment on the trial up to and including this month.	
A2 - 1.11	Cumulative Number of potential participants screened by the trial up to and including this month.	
A2 - 1.12	Cumulative Number of participants actually enrolled on the trial up to and including this month.	
A2 - 1.13	Cumulative Number of participants retained on the trial up to and including this month.	
A2 - 1.14	Success of enrolment for the trial - % of expected enrolment on the trial up to and including this month divided by Cumulative Number of participants actually enrolled on the trial up to and including this month.	
A2 - 1.15	Outcome of screening - % of cumulative Number of potential participants screened by the trial up to and including this month divided by Cumulative Number of participants actually enrolled on the trial up to and including this month.	
A2 - 1.16	Number of participants who kept appointments this month Inside Window Outside Window	
A2 - 1.17	Number of participants who missed appointments this month	
A2 - 1.18	Cumulative Number of defaulters or lost to follow up on the trial up until and including this month	
A2 - 1.19	Comments:	

Tools - SET A3

Inventory of CSE alongside GPP Guidelines

When to complete

- Monthly.
- This form is to be compiled monthly at the end of each month and the information should be extracted from your notes and minutes.

Number to complete

• One form per month addressing all GPP alignment and linkages.

Estimated Time

• 10 minutes.

TOOL A3 – Compilation of Clinical Trial Data

Instructions: This form is to be compiled monthly - at the end of each month and the information should be extracted from clinical trial recruitment and retention data.

SECTION 1: GENERA	L INFORMATION	
A3 - 1.0	NAME OF TRIAL	
A3 - 1.1	PROTOCOL/SUB-STUDY NUMBER	
A3 - 1.2	STUDY SITE	
A3 - 1.3	MONTH BEING COMPILED (all data will be collected about this month) Choose one:	☐ JANUARY ☐ FEBRUARY ☐ MARCH ☐ APRIL ☐ MAY ☐ JUNE ☐ JULY ☐ AUGUST ☐ SEPTEMBER ☐ OCTOBER ☐ NOVEMBER ☐ DECEMBER
A3 - 1.4	YEAR	20
A3 - 1.5	YEAR OF TRIAL Choose one	YEAR ONE OF TRIAL YEAR TWO OF TRIAL YEAR THREE OF TRIAL YEAR FOUR OF TRIAL
A3 - 1.6	PERSON COMPILING	

SECTION 2: INVENTORY of COMMUNITY ENGAGEMENT – Based on GPP Guidelines

Note - CSH - community stakeholders BSH - broader stakeholders

A3 - 1.6	SUGGESTIONS RECEIVED FROM CSE REG	ARDING FORMATIVE RESEARCH PROCESS					
A3 - 1.6-1	During the month was there CSH or BSH	engagement of any	engagement of any kind in FORMATIVE RESEARCH PROCESS?				
A3 - 1.6-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A	A3 1.5-5)				
A3 - 1.6-3	If yes, were the engagements above				CSH		BSH
	managed internationally, regionally, nationally or locally?	Internationally					
	(enter frequency for the month for each)	Nationally					
		Regionally					
		Locally					
A3 - 1.6-4	If yes, through which different mechanisms? (e.g. community				Frequency of Different Mechanisms		
	scientific subcommittee, concept	Community Scientific Subcommittee					
	presentation to CAB, etc). (enter frequency for the month for each)	Other Community Structures					
		Other					
A3 - 1.6-5	Describe any suggestion made DURING		Acted Up	on (Y)		Acted Up	on (Y)
	THE MONTH specifically by the <u>CSH</u> and <u>BSH</u> regarding the FORMATIVE	1)		6)			
	RESEARCH PROCESS. And indicate with a Y if it was acted			7)			
and indicate with a Y if it was acted upon.	,		8)				
		4)		9)			
		5)		10)			
A3 - 1.7	SUGGESTIONS RECEIVED FROM CSE REG						
A3 - 1.7-1	During the month was there CSH or BSH CSH BSH None	engagement of any kind in FORMATIVE RESEARCH PROCESS?					
A3 - 1.7-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A	A3 1.5-5)				
A3 - 1.7-3	If yes, were the engagements above				CSH		BSH
	managed internationally, regionally, nationally or locally?	Internationally					
	(enter frequency for the month for each)	Nationally					
		Regionally					
		Locally					
A3 - 1.7-4	If yes, through which different				Frequency of Different Mechanisms		nisms
	mechanisms? (e.g. community scientific subcommittee, concept	Community Scientific Subcommittee					
	presentation to CAB, etc). (enter frequency for the month for each)	Other Community Structures					
		CAB/CAG/CR					
		Other					
A3 - 1.7-5	Describe any suggestion made DURING THE MONTH specifically by		Acted Up	on (Y)		Acted Up	on (Y)
	the <u>CSH</u> and <u>BSH</u> regarding the <u>TRIAL</u>	1)			6)		
	PROTOCOL DEVELOPMENT? And indicate with a Y if it was acted	2)			7)		
	upon.	3)			8)		
		4)			9)		
		5)			10)		l

A3 - 1.8	SUGGESTIONS RECEIVED FROM CSE REGARDING INFORMED CONSENT FORMS AND PROCESSES						
A3 - 1.8-1	During the month was there CSH or BSH engagement of any kind in INFORMS AND PROCESSES ? CSH BSH None						
A3 - 1.8-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A	A3 1.7-5)				
A3 - 1.8-3	If yes, were the engagements above				CSH		BSH
	managed internationally, regionally, nationally or locally?	Internationally					
	(enter frequency for the month for each)	Nationally					
		Regionally					
		Locally					
A3 - 1.8-4	If yes, through which different				Frequency of Diffe	rent Mecha	anisms
	mechanisms? (e.g. community scientific subcommittee, concept	Community Scientif	fic Subco	mmittee			
	presentation to CAB, etc). (enter frequency for the month for each)	Other Community S	tructures				
		CAB/CAG/CR					
		Other					
A3 - 1.8-5	Describe any suggestion made DURING		Acted Up	on (Y)		Acted Up	on (Y)
	THE MONTH specifically by the <u>CSH</u> and <u>BSH</u> regarding the <u>INFORMED</u>	1)			6)		
	CONSENT FORMS AND PROCESSES. And indicate with a Y if it was acted	2)			7)		
	upon.	3)		8)			
		4)			9)		
		5) 10)					
A3 - 1.9	SUGGESTIONS RECEIVED FROM CSE REG						
A3 - 1.9 A3 - 1.9-1	SUGGESTIONS RECEIVED FROM CSE REG During the month was there CSH or BSH CSH BSH None				NICATIONS PLAN?		
	During the month was there CSH or BSH		kind abou		NICATIONS PLAN?		
A3 - 1.9-1 A3 - 1.9-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above	CSH SH	kind abou		NICATIONS PLAN? CSH		BSH
A3 - 1.9-1	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements?	CSH SH	kind abou				BSH
A3 - 1.9-1 A3 - 1.9-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally,	CSH SH SH N/A – none (skip to A	kind abou				BSH
A3 - 1.9-1 A3 - 1.9-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH SH SH Skip to A	kind abou				BSH
A3 - 1.9-1 A3 - 1.9-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH SH SH SKIP to A Internationally Nationally	kind abou				BSH
A3 - 1.9-1 A3 - 1.9-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each)	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally	kind abou	t COMMUN			
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept	CSH SH N/A – none (skip to A Internationally Nationally Regionally	kind abou	t COMMUN	CSH		
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally	kind abou	t COMMUN	CSH		
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientification	kind abou	t COMMUN	CSH		
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif	kind abou	t COMMUN	CSH		
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made	csh BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR	kind abou	mmittee	CSH		anisms
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1)	kind abou	mmittee	CSH CSH Frequency of Diffe	rent Mecha	anisms
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the COMMUNICATIONS PLAN?	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1) 2)	kind abou	mmittee	CSH CSH Frequency of Diffe G G 7)	rent Mecha	anisms
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientiff Other Community S CAB/CAG/CR Other 1) 2) 3)	kind abou	mmittee	CSH CSH Frequency of Diffe G G 7) 8)	rent Mecha	anisms
A3 - 1.9-1 A3 - 1.9-2 A3 - 1.9-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the COMMUNICATIONS PLAN? And indicate with a Y if it was acted	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1) 2)	kind abou	mmittee	CSH CSH Frequency of Diffe G G 7)	rent Mecha	anisms

A3 - 1.10	SUGGESTIONS RECEIVED FROM CSE REGARDING TRIAL RESULTS DISSEMINATION							
A3 - 1.10-1	During the month was there CSH or BSH	engagement of any l	kind in <u>TR</u>	ial resul	TS DISSEMINATION?			
A3 - 1.10-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A	A3 1.9-5)					
A3 - 1.10-3	If yes, were the engagements above				CSH		BSH	
	managed internationally, regionally, nationally or locally?	Internationally						
	(enter frequency for the month for each)	Nationally						
		Regionally						
		Locally						
A3 - 1.10-4	If yes, through which different mechanisms? (e.g. community				Frequency of Diffe	rent Mecha	anisms	
	scientific subcommittee, concept	Community Scientif	fic Subco	mmittee				
	presentation to CAB, etc). (enter frequency for the month for each)	Other Community S	tructures					
		CAB/CAG/CR						
		Other						
A3 - 1.10-5	Describe any suggestion made DURING		Acted Up	on (Y)		Acted Up	on (Y)	
	THE MONTH specifically by the <u>CSH</u> and <u>BSH</u> regarding the <u>TRIAL RESULTS</u>	1)			6)			
	DISSEMINATION. And indicate with a Y if it was acted	2)			7)			
	upon.	3)			8)			
		4)			9)			
		5)			10)			
A3 - 1.11	UGGESTIONS RECEIVED FROM CSE REGARDING DEVELOPMENT OF ISSUES PLAN							
A3 - 1.11-1	During the month was there CSH or BSH CSH BSH None					<u>N</u> ?		
A3 - 1.11-1 A3 - 1.11-2	During the month was there CSH or BSH		kind abou	t <u>DEVELO</u> F		<u>N</u> ?		
A3 - 1.11-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above	CSH BSH	kind abou	t <u>DEVELO</u> F			BSH	
	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements?	CSH BSH	kind abou	t <u>DEVELO</u> F	MENT OF ISSUES PLA		BSH	
A3 - 1.11-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally,	CSH BSH N/A – none (skip to A	kind abou	t <u>DEVELO</u> F	MENT OF ISSUES PLA		BSH	
A3 - 1.11-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH BSH SH N/A – none (skip to A	kind abou	t <u>DEVELO</u> F	MENT OF ISSUES PLA		BSH	
A3 - 1.11-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH BSH SH Skip to A	kind abou	t <u>DEVELO</u> F	MENT OF ISSUES PLA		BSH	
A3 - 1.11-2	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each)	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally	kind abou	t <u>DEVELOP</u>	MENT OF ISSUES PLA			
A3 - 1.11-2 A3 - 1.11-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept	CSH SH S	kind abou	t <u>DEVELOP</u>	CSH			
A3 - 1.11-2 A3 - 1.11-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally	kind abou	t <u>DEVELOP</u>	CSH			
A3 - 1.11-2 A3 - 1.11-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientification	kind abou	t <u>DEVELOP</u>	CSH			
A3 - 1.11-2 A3 - 1.11-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientify Other Community S	A3 1.10-5) fic Subco	t <u>DEVELOP</u>	CSH			
A3 - 1.11-2 A3 - 1.11-3	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other	A3 1.10-5) fic Subco	mmittee	CSH CSH Frequency of Differ		anisms	
A3 - 1.11-2 A3 - 1.11-3 A3 - 1.11-4	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the DEVELOPMENT	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientifi Other Community S CAB/CAG/CR Other	kind abou	mmittee	CSH CSH Frequency of Diffe [] [rent Mecha	anisms	
A3 - 1.11-2 A3 - 1.11-3 A3 - 1.11-4	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the DEVELOPMENT OF ISSUES PLAN?	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1) 2)	kind abou	mmittee	CSH CSH Frequency of Differ CI	rent Mecha	anisms	
A3 - 1.11-2 A3 - 1.11-3 A3 - 1.11-4	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the DEVELOPMENT	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientiff Other Community S CAB/CAG/CR Other 1) 2) 3)	kind abou	mmittee	CSH CSH Frequency of Diffe [] [] 6) 7) 8)	rent Mecha	anisms	
A3 - 1.11-2 A3 - 1.11-3 A3 - 1.11-4	During the month was there CSH or BSH CSH BSH None If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the DEVELOPMENT OF ISSUES PLAN? And indicate with a Y if it was acted	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1) 2)	kind abou	mmittee	CSH CSH Frequency of Differ CI	rent Mecha	anisms	

A3 - 1.12	SUGGESTIONS RECEIVED FROM CSE REGARDING PROCEDURES FOR PARTICIPANT EXIT FROM TRIAL						
A3 - 1.12-1	During the month was there CSH or BSH	engagement of any l	kind in <u>PR</u>	OCEDURE	S FOR PARTICIPANT E)	KIT FROM 1	TRIAL?
A3 - 1.12-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A	A3 1.11-5)				
A3 - 1.12-3	If yes, were the engagements above				CSH		BSH
	managed internationally, regionally, nationally or locally?	Internationally					
	(enter frequency for the month for each)	Nationally					
		Regionally					
		Locally					
A3 - 1.12-4	If yes, through which different				Frequency of Diffe	rent Mecha	anisms
	mechanisms? (e.g. community scientific subcommittee, concept	Community Scientif	fic Subco	mmittee			
	presentation to CAB, etc). (enter frequency for the month for each)	Other Community S	tructures				
		CAB/CAG/CR					
		Other					
A3 - 1.12-5	Describe any suggestion made DURING		Acted Up	on (Y)		Acted Up	on (Y)
	THE MONTH specifically by the <u>CSH</u> and <u>BSH</u> regarding the <u>PARTICIPANT</u>	1)			6)		
	EXIT FROM TRIAL.	2)			7)		
	And indicate with a Y if it was acted upon.	3)		8)			
		4)			9)		
		5)			10)		
A3 - 1.13	SUGGESTIONS RECEIVED FROM CSE REG	ARDING INTERVENTION	ON AND TI	RIAL PROD	UCT IMPLEMENTATION	N	
A3 - 1.13-1	During the month was there CSH or BSH en	gagement of any kind	about INT	ERVENTION	I AND TRIAL PRODUCT I	INADI ENAENI	
A3 - 1.13-2	CSH BSH None				VAND MIAL MODOUT	IMPLEMEN	<u>TATION</u> ?
A3 - 1.13-2	If yes, please enter how many engagements?	CSH BSH N/A – none (skip to A			TAND HIML HOUSET	IMPLEMEN	TATION?
A3 - 1.13-2	If yes, please enter how many engagements? If yes, were the engagements above	CSH BSH			CSH		TATION? BSH
	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally,	CSH BSH					
	If yes, please enter how many engagements? If yes, were the engagements above	CSH BSH N/A – none (skip to A					
	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH BSH N/A – none (skip to A					
	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally?	CSH BSH N/A – none (skip to A Internationally Nationally					
	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different	CSH BSH N/A – none (skip to A Internationally Nationally Regionally					BSH
A3 - 1.13-3	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept	CSH BSH N/A – none (skip to A Internationally Nationally Regionally	A3 1.12-5)		CSH		BSH
A3 - 1.13-3	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally	\3 1.12-5) fic Subco	mmittee	CSH		BSH
A3 - 1.13-3	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientification	\3 1.12-5) fic Subco	mmittee	CSH		BSH
A3 - 1.13-3	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc).	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientifi	1.12-5) fic Subco	mmittee	CSH		BSH
A3 - 1.13-3	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientifi Other Community S CAB/CAG/CR	1.12-5) fic Subco	mmittee	CSH		BSH
A3 - 1.13-3 A3 - 1.13-4	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1)	fic Subco	mmittee	CSH CSH Frequency of Diffe	rent Mecha	BSH
A3 - 1.13-3 A3 - 1.13-4	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the INTERVENTION AND TRIAL PRODUCT	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientifi Other Community S CAB/CAG/CR Other	fic Subco	mmittee	CSH CSH Frequency of Diffe	rent Mecha	BSH
A3 - 1.13-3 A3 - 1.13-4	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the INTERVENTION AND TRIAL PRODUCT IMPLEMENTATION? And indicate with a Y if it was acted	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientif Other Community S CAB/CAG/CR Other 1) 2) 3)	fic Subco	mmittee	CSH CSH Frequency of Diffe G G T) 8)	rent Mecha	BSH
A3 - 1.13-3 A3 - 1.13-4	If yes, please enter how many engagements? If yes, were the engagements above managed internationally, regionally, nationally or locally? (enter frequency for the month for each) If yes, through which different mechanisms? (e.g. community scientific subcommittee, concept presentation to CAB, etc). (enter frequency for the month for each) Describe any suggestion made DURING THE MONTH specifically by the CSH and BSH regarding the INTERVENTION AND TRIAL PRODUCT IMPLEMENTATION?	CSH BSH N/A – none (skip to A Internationally Nationally Regionally Locally Community Scientifi Other Community S CAB/CAG/CR Other	fic Subco	mmittee	CSH CSH Frequency of Diffe	rent Mecha	BSH

Linkages

For each type of linkage, choose YES (Y) or No (N) if linkage has been made during the MONTH. If yes, indicate how many of each nature.

Q# A3- 1.14	QUESTION Kind of linkages with CSH & BSH based		Nature of Linkages				
	structures		Very strong	Strong	Average	Weak	Very Weak
A3- 1.14-1	NEW Linkages with Community Based Organisations.	ΥN					
A3- 1.14-2	NEW Linkages with Civil Society Organizations.	ΥN					
A3- 1.14-3	NEW Linkages with Professional Associations.	ΥN					
A3- 1.14-4	NEW Linkages with Tertiary Institutions/ Vocational.	ΥN					
A3- 1.14-5	NEW Linkages with Secondary Schools.	Y N					
A3- 1.14-6	NEW Linkages with Primary Schools.	ΥN					
A3- 1.14-7	NEW Linkages with Industries /Shops/ Markets.	ΥN					
A3- 1.14-8	NEW Linkages with Faith Based Organizations – churches/mosques/ temples etc.	Y N					
A3- 1.14-9	NEW Linkages with clinics and hospitals.	Y N					
A3- 1.14-10	Other NEW Linkages.	ΥN					

INFORMATION GIVING - List the number and types of information giving conducted during the month

A3- 1.15	QUESTION Kind of Trainings Conducted					
	TYPE OF TRAINING this month	NUMBER OF TRAININGS this month	DETAILS OF TRAINING this month			
A3- 1.15-1						
A3- 1.15-2						
A3- 1.15-3						
A3- 1.15-4						
A3- 1.15-5						
A3- 1.15-6						
A3- 1.15-7						
A3- 1.15-8						
A3- 1.15-9						

Tools - SET B1

Community Stakeholder Interview

When to complete

Monthly - Quarterly.

Target

- Community based organisations (CBOs), the families and friends of trial participants, schools, trial site staff, local religious institutions, traditional leaders, local health service providers, home care workers from each relevant location or region represented in your trials' catchment area or as seen appropriate by your team.
- Be reminded that this interview is not targeting broader stakeholders (form B3) which would include nongovernmental organisations (NGOs), local health department directors, managers or policy makers, politicians, local media and medical professionals.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 per month.
- This will spur you on to actively reach out to new stakeholders every month.
- The more committed you are to scheduling key informant interviews with a wide array of community stakeholders and enquiring about their experience or lack of experience with your unit or trial, means that over time you will have a rich data set which will have more value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

½ hour.

TOOL B1 – COMMUNITY STAKEHOLDER INTERVIEW

SECTION 1: GENERAL INFORMATION					
B1 - 1.0	INTERVIEW NUMBER				
B1 - 1.1	NAME OF RESEARCH TRIAL PROTOCOL or SUB-STUDY NUMBER				
B1 - 1.2	STUDY SITE				
B1 - 1.3	DATE OF INTERVIEW	DAY MONTH CYEAR			
B1 - 1.4	NAME OF INTERVIEWER				
B1 - 1.5	TIME INTERVIEW STARTED	HOUR MINUTE			

Preamble: Note to interviewer: Depending on your institutions rules, you may need to develop a consent form. Note — that this is a monitoring and evaluation tool and not a research tool.

Hello – I am the community liaison officer/manager for this research unit. To be sure that we are communicating and engaging with the different stakeholders properly around our studies, we would like to speak to you to find out more about how you have been reached by this study. I have a few questions to ask you and request that you be completely honest in your reply. We need to hear what you know about these studies and how you were reached. This will help to make us better at effectively engaging with various stakeholders around the clinical research trials we are conducting. Thank you for your time.

SECTION 2: INTERVI	EW		
B1 - 1.6	Mark the sex of the interviewee	Male	
		Female	
B1 - 1.7	What is the highest level of schooling you have completed?	I never attended school	
		I did part of Primary – incomplete	
		I completed Primary	
		I did part of Secondary - incomplete	
		I completed Secondary	
		I attended College	
		I attended University - Tertiary	

B1 - 1.8	Mark the kind of community or broader stakeholder this interviewee represents. You may not need to ask this question if you can establish the answer on your own.	Type your response and then match your response to a category below — if match to your response, choose other. NOTE — Do not use this questionnaire if the interviewee is a TRIAL	there is no
		PARTICIPANT (use C1), or a PROSPECTIVE TRIAL PARTICIPANT (use C2) or a CAB REPRESENTATIVE (use C1) OR BROADER STAKEHOLDER (use B3)	
		INDIVIDUAL RESIDENT IN THE TARGET AREA	
		COMMUNITY BASED ORGANISATION STAFF	
		SCHOOL TEACHER	
		YOUTH WORKER	
		LOCAL HEALTH FACILITY STAFF	
		TRADITIONAL HEALER	
		LOCAL FAITH BASED LEADER	
		LOCAL LEADERSHIP - TRADITIONAL	
		COMMUNITY HEALTH WORKER	
		Other (specify)	
B1 - 1.9	Do you know of or have you heard of the research unit I represent as a	Yes	
	community liaison officer/manager?	No (SKIP TO)	
B1 - 1.10 QUAL	If you know - please share with me, what this organization/institute does in your community?	Type your response and then match your response to a category belo there is no match to your response, choose other.	ow – if
		POSTCODE –select best option from below	
		I don't know what your organisation/group/Institute does (NO to question above)	
		Your organisation treats adults/or children who are sick	
		Your organisation teaches/trains about health related issues	
		Your organisation conducts health related (TB/HIV) prevention/treatment research	
		Other (specify)	
		ion does – please provide a thorough briefing at this point.	
B1 - 1.11	This organization works through clinics/health facilities to reach	Yes	
	people - do you know where any of the research clinics are located?	No (SKIP TO B1 – 1.13)	

B1 - 1.12	If yes, to the question above, where do you live relative to one of the research	I don't know the clinic is/I don't know about the research				
	clinics?	5 – 15 minutes on foot				
		16 – 30 minutes by foot				
		>30 minutes by foot				
		5 – 15 minutes in a bus/taxi/daladala/matatu				
		16 – 30 minutes in a bus/taxi/daladala/matatu		Γ	1	
		>30 minutes in a bus/taxi/daladala/matatu				
		Note: if the respondent does not know about the research sit know where the research sites are located – you may need to respondent can tell you where she or he lives in relation to on sites.	o elal	borate	e so t	
B1 - 1.13	How well known is the organization that is conducting the study in	Very well known throughout my community				
	the community that you currently	Well known in trial sites or around research clinics only				
	represent?	Only known by small groups of people				
		In general not known by people I mingle with				
		I can't answer – as I don't know about the work that this organization is doing/have never heard about this organisation				
		List of studies – indicated in Setup	S1	S2	S3	S4
B1- 1.14	How well known do you think these	I don't know how well known this specific study is				
	studies are in the communities where you live?	The specific study is very well known throughout the target communities				
	Note: list all the studies underway that you are responsible for as CLO	The specific study is only known by small groups of people				
		In general the specific study is not known by anyone apart from trial participants				
		The specific study is only known by health staff who have been oriented to the study				
		The specific study is only known by health staff who have been oriented to the study AND trial participants				
		I can't answer – as I don't know about this specific study				
B1 - 1.15 QUAL	This organisation carries out clinical research to improve the health of populations. Can you share anything you know about the research that this organisation conducts?	Type the response here.				
		I have never heard about the organisation or this specific research				
		List of studies – indicated in Setup	S1	S2	S2	S4
B1 - 1.16	How well do you think you understand the	I know nothing about this research				
	purpose of these research studies?	I understand this trial very well – I have no questions				
		I understand their trial but I still have a few questions		H		H
		I do not understand this trial - I have many questions				H
			ıШ		السار	

		List of studies indicated in Ostum	01	00	00	0.4
		List of studies – indicated in Setup	S1	S2	S3	S4
B1 - 1.17	How involved/engaged/occupied are you with the work /research – how	Never				Ш
	often do you do something to do with this study?	Every day				
	,	Every week at least once				
		Every month at least once				
		Every 3 months at least once				
		At least twice a year				
		Other (specify)				
		List of studies – indicated in Setup	S1	S2	S3	S4
B1 - 1.18	Would you like to be more or less involved in these clinical trials?	MORE INVOLVED				
	involved in these clinical trials?	THE SAME INVOLVEMENT				
		LESS INVOLVED				
		INDIFFERENT/DON'T CARE/DON'T KNOW ABOUT IT				
B1 - 1.19 QUAL	Can you explain why you feel this way (referring to response above) and how you imagine, in your position you could support or be more involved with this research work?	Type the response here.				
B1 - 1.20	Are you very satisfied, satisfied, unsatisfied, very satisfied or indifferent	No one consults with me/l have never heard about this research				
	about the way the research team on this trial consults with you as a	Indifferent/Don't care				
	community stakeholder?	Unsatisfied				
		Satisfied				
		Very Satisfied				
B1 - 1.21 QUAL	Please tell me why you feel this way (as described in the above question)?	Type the response here.				
B1 - 1.22	Have you ever made suggestions to the	YES				
	researchers/research staff of this study about things they can do or change?	NO (SKIP B1 - 1.24)		Γ	7	
		Not applicable as have never heard of this study before (SKIP B1 - 1.24)				
B1 - 1.23 QUAL	Please share any suggestions on how things could be changed to improve the way the trials are run in order to improve the relationship with the stakeholders, including health personnel or policy makers?	Type the response here.	•			
B1 - 1.24	Have you been aware of any negative	YES				
	messages about this study circulating in this or the surrounding community?	NO (SKIP B1 - 1.26)			7	
		Not applicable as have never heard of this study before today (SKIP B1 - 1.25)				
B1 - 1.25 QUAL	Can you share any of the negative messages/rumours you may have heard about this study?	Type the response here.				

B1 - 1.26	Have you been aware of any positive messages about this study circulating	YES	
	in your community?	NO	
		Not applicable as have never heard of this study before	
B1 - 1.27 QUAL	Can you share any of the positive messages you may have heard about this study?	Type the response here.	
B1 - 1.28	Over the past 6 months, how would you rate the strength of the community's relationship/ engagement with these	Very Strong The community is involved in all (90 - 100%) aspects of the research, from planning through dissemination of the research.	
	various research projects?	Strong The community is involved in most (70 to 89%) aspects of the research but no necessarily all development and planning.	
		Medium The community is involved in about 60 to 70% of the research process.	
		Weak The community is involved in very few aspects (40 -60%) of the research activities.	
		Very Weak The community is involved in less than 40% of the research activities.	
		I don't know – Not in a position to judge	
		List of studies – indicated in Setup	S1 S2 S3 S4
B1 - 1.29	How did you first hear about this/these research studies?	I have never heard about any of these research studies	
	research studies:	I heard about this research through a colleague	
		I heard about this research through a committee meeting	
		I heard about this research through the health department	
		I heard about this research through the radio/TV/ newspaper/posters/flyers	
		I heard about this research while at a health event	
		I heard about this research while at a health training	
		I was visited by the study reps at my place of work	
		I was informed by our coordinator/supervisor at work	
		I was informed when someone from the research unit visited my organisation/company/resource	
		I was informed through a conference/briefing workshop	
		Other (specify)	
		List of studies – indicated in Setup	S1 S2 S3 S4
B1 - 1.30	How often do you receive an update about this research?	I never receive updates	
	about tills research:	I receive updates – irregularly/from time to time	
		I receive updates every day	
		I receive updates every week	
		I receive updates every two weeks	
		I receive updates every month	
		I receive updates every two months	
		I receive updates every 3 months	
		I receive updates every 4 – 6 months	
		I receive updates once a year	
		I receive updates every few years	
		Other (specify)	

B1 - 1.31 QUAL	Which groups of people with whom you work do you think should know about	le with whom versions, choose other. vork do you think ld know about POSTCODE –select best option from below –choose multiple					
	this research?	INDIVIDUAL RESIDENTS I	N THE TARGET AREA				
		PEOPLE AFFECTED BY TH	HE DISEASE BEING STUDIED				
		PEOPLE WHO WILL BENE	FIT FROM THE INTERVENTION BEING STUDIED				
		PEOPLE WHO MAY BE EL	IGIBLE TO PARTICIPATE IN THE STUDY				
		HEALTH ADVOCATE or AC	TIVIST				
		COMMUNITY BASED ORG	GANISATION STAFF				
		NON GOVERNMENTAL OF	RGANISATION STAFF				
		SCHOOL TEACHERS					
		STUDENTS/CHILDREN					
		LOCAL HEALTH FACILITY	STAFF/HEALTH WORKERS /COMMUNITY HEALTH WORKERS				
		LOCAL FAITH BASED LEA	ADERS				
		LOCAL LEADERSHIP – GO	OVERNMENT OR ELECTED				
		LOCAL LEADERSHIP – TF	RADITIONAL				
		LOCAL – DEPARTMENT C	OF HEALTH STAFF/MANAGERS				
		MEDIA PERSONNEL/JOU	RNALISTS				
		LOCAL BUSINESS OWNE	RS/BUSINESSES				
		LEGAL SPECIALISTS					
		LOCAL POLICY MAKERS					
		Other (specify)					
B1 - 1.32	Do you know a specific the research team or at		YES				
	whom you could speak		NO				
B1 - 1.33	Do you know about the Advisory Board/Commu	CAB – Community nity Advisory Group/CR –	YES				
	community representati appropriate to your stud	ives (please use a term	NO (SKIP B1 - 1.35)				
B1 - 1.34 QUAL	If you know about the C describe what you think		Type the response here				
B1 - 1.35	Time Interview Ended		□□HOUR □□MINUTE				
B1 - 1.36 QUAL	Observations – Comme Note down any further co		any lessons learned that require further follow up or sharing				
	Observation 1		Any Follow up required				
	Observation 2		Any Follow up required				
	Observation 3		Any Follow up required				
	Observation 4		Any Follow up required				

Tools - SET B2

Community Advisory Group Member or Community Representative Interview

When to complete

Monthly and Quarterly.

Target

• CAB Members or Community Representatives on a the advisory forum or the equivalent.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 per month.
- This will spur you on to actively reach out to new stakeholders every month.
- The more committed you are to scheduling key informant interviews with a wide array of community stakeholders and enquiring about their experience or lack of experience with your unit or trial, means that over time you will have a rich data set which will have more value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

½ hour.

TOOL B2 – CAB - ADVISORY GROUP MEMBER OR COMMUNITY REPRESENTATIVE INTERVIEW

SECTION 1: GENERAL INFORMATION					
B2 - 1.0	INTERVIEW NUMBER				
B2 - 1.1	NAME OF RESEARCH TRIAL PROTOCOL/SUB-STUDY NUMBER				
B2 - 1.2	STUDY SITE				
B2 - 1.3	DATE OF INTERVIEW	DDAY DMONTH DDD YEAR			
B2 - 1.4	NAME OF INTERVIEWER				
B2 - 1.5	TIME INTERVIEW STARTED	□□HOUR □□MINUTE			

Preamble: Note to interviewer: Depending on your institutions rules, you may need to develop a consent form. Note — that this is a monitoring and evaluation tool and not a research tool.

Hello — I am the community liaison officer/manager for this research unit. To be sure that we are communicating and engaging with the different stakeholders properly around our studies, we would like to speak to you to find out more about how you have been reached by this study. I have a few questions to ask you and request that you be completely honest in your reply. We need to hear what you know about these studies and how you were reached. This will help to make us better at effectively engaging with various stakeholders around the clinical research trials we are conducting. Thank you for your time.

SECTION 2: INTERVIEW					
B2 - 1.6	Mark the sex of the interviewee	Male			
		Female			
B2 - 1.7	What year were you born in? (estimate adequate)				
B2 - 1.8	What is the highest level of schooling you have completed?	I never attended school			
		I did part of Primary – incomplete			
		I completed Primary			
		I did part of Secondary - incomplete			
		I completed Secondary			
		I attended College			
		I attended University - Tertiary			

B2 - 1.9	Mark the kind of community or broader stakeholder this interviewee represents.		Type your response and then match your response to a category below — if there is no match response, choose other.					n to your
		NOTE – Do not u C1), or a PROSPL B3)	se this question ECTIVE TRIAL PA	naire if the intervi ARTICIPANT (use C	ewee is a TRIAL F C2) or a CHS (use	ARTICIPANT(use B1) or BHS (use		
		INDIVIDUAL RES	SIDENT IN THE	TARGET AREA				
		ADVOCATE or AC	CTIVIST					
		COMMUNITY BA	SED ORGANISA	ATION STAFF				
		SCHOOL TEACH	ER					
		YOUTH WORKER	R				[
		LOCAL HEALTH	FACILITY STAFF	=				
		TRADITIONAL HI	EALER					
		LOCAL FAITH BA	ASED LEADER					
		LOCAL LEADERS	SHIP – GOVERN	MENT OR ELECT	ED			
		LOCAL LEADERS	SHIP - TRADITIO	DNAL			[
		COMMUNITY HE	ALTH WORKER					
		LOCAL BUSINES	S OWNERS					
		LEGAL EXPERT						
		MEDIA PERSON	NEL/JOURNALI	STS				
		LOCAL POLICY N	MAKERS				[
		LOCAL BUSINES	SS					
		NON GOVERNME	ON GOVERNMENTAL ORGANISATION STAFF					
		Other (specify)						
B2 - 1.10	How many months or years have you	0-3 months	4-6 months	7-12 months	13-24 months	2-3 years	>3 ye	ears
	participated on this study's advisory group - CAB?							
B2 - 1.11	What is your role as a CAB member?	Type your respon response, choose		tch your response	e to a category be	low — if there is no	match	n to your
		POSTCODE - Ch	noose all that a	pply.				
		TO PROVIDE INP	PUT ON CLINICA	L TRIAL PLANS	AND PROTOCOL			
		TO CONSULT WI from outside res		RCH TEAM – to g	ather opinions/	ideas/suggestion	s	
		TO OFFER OUR	SUPPORT – to 1	acilitate the res	earch			
				R SECTORS & KE ce in the commu		S INFORMED – to)	
		-		E ON THE RESE				
				LISTEN TO US & our communities		EEDBACK on how	'	
		Other (specify)						
		Other (specify)						

B2 - 1.12	How often does research team consult	Every month				
	with you as a CAB?	Every two months				
		4 times a year				
		2- 3 times a year				
		Never				
DO 110	Where do you live relative to one of the					
B2 - 1.13	Where do you live relative to one of the research clinics?	5 – 15 minutes on foot				
	Note: if the respondent does not know about the research sites or does not know	16 – 30 minutes by foot				
	where the research sites are located – you may need to elaborate.	>30 minutes by foot				
		5 – 15 minutes in a bus/taxi/daladala/matatu				
		16 – 30 minutes in a bus/taxi/daladala/matatu				
		>30 minutes in a bus/taxi/daladala/matatu				
B2 - 1.14	How well known is the organization that is conducting the study in the	Very well known throughout my community				
	community that you represent?	Well known in trial sites or around research clinics only				
		Only known by small groups of people				
		In general not known by people I mingle with				
		I can't answer – as I don't know about the work that this organization is doing/have never heard about this organisation	n			
		List of studies – indicated in Setup	S1	S2	S3	S4
B2- 1.15	How well known do you think these studies are in the communities or groups that you represent on the CAB?	I don't know how well known this specific study is				
		The specific study is very well known throughout the target communities				
	Note to interviewer: Make sure to query using the list all the studies underway that	The specific study is only known by small groups of people				
	you are responsible for as CLO.	In general the specific study is not known by anyone apart from trial participants				
		The specific study is only known by health staff who have been oriented to the study				
		The specific study is only known by health staff who have been oriented to the study AND trial participants				
		I can't answer – as I don't know about this specific study				
B2 - 1.16 QUAL	This organisation carries out clinical research to improve the health of populations.	Type your response and then match your response to a category to is no match to your response, choose other.	elow	elow – if there		
	Can you share anything you know about the research that this organisation conducts?	I have never heard about the organisation or this specific			_	
		research				
		List of studies – indicated in Setup	S1	S2	S2	S4
B2 - 1.17	How well do you think you understand the purpose of these research studies?	I know nothing about this research				
		I understand this trial very well – I have no questions				
		I understand their trial but I still have a few questions				
		I do not understand this trial — I have many questions				
		List of studies – indicated in Setup	S1	S2	S2	S4
B2 - 1.18	How involved/engaged/occupied are you with the work /research – how often do you do something to do with	Never				
		Every day				
	this study?	Every week at least once				
		Every month at least once				
	I.	I.				

		Every 3 months at least once						
		At least twice a year						
		Other (specify)						
		List of studies – indicated in Setup	S1	S2	S3	S4		
B2 - 1.19	Would you like to be more or less involved in these clinical trials?	MORE INVOLVED						
	in these chinical trials?	THE SAME INVOLVEMENT						
		LESS INVOLVED						
		INDIFFERENT/DON'T CARE/DON'T KNOW ABOUT IT						
B2 - 1.20 QUAL	Can you explain why you feel this way (referring to response above) and how you imagine, in your position you could support or be more involved with this research work?	Type your response and then match your response to a category be match to your response, choose other	nelow	– if t	'here i	s no		
B2 - 1.21	How satisfied are you with the way the research team on this trial consults	No one consults with me/l have never heard about this research						
	with you through the CAB?	Indifferent/Don't care						
		Unsatisfied						
		Satisfied						
		Very Satisfied						
B2 - 1.22 QUAL	Please tell me why you feel this way – very satisfied, satisfied, unsatisfied, indifferent /don't care (as described in the above question)?	Type your response and then match your response to a category be match to your response, choose other.	nelow	– if t	here i	s no		
B2 - 1.23	Overall, since you joined the CAG/ CAB,have you ever made suggestions to the researchers/research staff of this study about things they can do or change?	YES						
		NO						
		DON'T KNOW						
B2 - 1.24 QUAL	Please explain your answer further – whether the research team has listened to your suggestions/made changes based on your suggestions.	Type the response here.						
B2 - 1.25	Have you been aware of any negative	YES						
	messages about this study circulating in this or the surrounding community?	NO (SKIP B2 - 1.27)						
		Not applicable as have never heard of this study before today (SKIP B2 - 1.27)						
B2 - 1.26 QUAL	Can you share any of the negative messages/rumours you may have heard about this study?	Type the response here.						
B2 - 1.27	Have you been aware of any positive messages about this study circulating in your community?	YES						
		NO						
		Not applicable as have never heard of this study before today						
B2 - 1.28 QUAL	Can you share any of the positive messages you may have heard about this study?	Type the response here.						

B2 - 1.29	Over the past 6 months, how would you rate the strength of the community's relationship/ engagement with the	Very Strong The community is involved in all (90 - 100%) aspects of the research, from planning through dissemination of the research.	
	research team?	Strong The community is involved in most (71 to 89%) aspects of the research but no necessarily all development and planning.	
		Medium The community is involved in about 60 to 70% of the research process.	
		Weak The community is involved in very few aspects (40 - 59%) of the research activities.	
		Very Weak The community is involved in less than 40% of the research activities.	
		I don't know – Not in a position to judge	
B2 - 1.30	How were you selected to participate in the CAG/CAB/CR?	I was asked to join by the research team based on my position in the community	
		I was nominated/put forward/voted by people in the community/my sector	
		I heard about the study & volunteered independently	
		I am a leader in the community and I always represent the community	
		Other (specify)	
B2 - 1.31	Do you think the way in which people	YES	
	are selected to participate in the CAB is fair and effective?	NO	
		DON'T KNOW – NOT SURE – NOT AWARE	
B2 - 1.32 QUAL	Please share how you feel about how people are selected to participate in the CAG/CAB/CR?	Type the response here.	
B2 - 1.33	Do you think the people currently on	YES	
	the CAB represent all the important portions of the community who may	NO	
	be affected or may have an impact in an important way beyond this research study?	Don't know – not sure	
B2 - 1.34	How satisfied are you with the way the	Very satisfied	
	CAB/ has worked as a study advisory structure during the last 6 months?	Satisfied	
		Disappointed – Low satisfaction	
		Unsatisfied	
		Don't Know	
B2 - 1.35 QUAL	Please share the way you feel about the way the CAB/CAG/CR works as an advisory structure?	Type the response here.	
B2 - 1.36	As a CAB member, do you feel that you are part of the research team, or an independent "watchdog" over the research?	I feel part of the research team	
		I feel like an independent watchdog over the research	
		I don't feel like I am part of the research nor do I feel like I am an independent watchdog over the research	

B2 - 1.37	How much have you valued your participation in the CAB?	I have valued it greatly	
	participation in the GAD:	I have valued it	
		I have valued it very little	
		I have not valued it	
		I am indifferent –I don't care	
B2 - 1.38 QUAL	Please describe the reasons why you have valued or not valued your participation in the CAB?	Type the response here.	
B2 - 1.39	At present, how interested are you personally in this research study?	Very interested	
	personally in this research study:	Interested	
		Not interested	
		Indifferent	
B2 - 1.40 QUAL	Can you share why you are interested or not interested in the study?	Type the response here.	
B2 - 1.41	In general how much do you think the research team has trusted and valued	The research team has trusted and valued us	
	the contribution of the CAB advisory group?	The research team has not trusted and valued us	
	group.	DON'T KNOW – difficult to assess	
B2 - 1.42	In general, how much do you think the members CAB have trusted and valued	In general we do trust and value the research team	
	the research team?	In general we do not trust and value the research team	
		DON'T KNOW	
B2 - 1.43 QUAL	Please can you explain to me in your own words why you feel this way (I trust the research team, I don't trust the research team; I am not sure – my opinion changes)	Type the response here.	
B2 - 1.44	Apart from the CAB have you met to discuss this study in any way on other	YES	
	occasions during the last 6 months?	NO	
B2 - 1.45	In the last 6 months have you discussed this study in your community	YES	
	when you are going about your other business?	NO	
B2 - 1.46	Do you believe that this study	YES	
	has brought any benefits to your community?	NO (SKIP B2-1.48)	
		NOT YET (SKIP B2-1.48)	
		DON'T KNOW (SKIP B2-1.48)	
B2 - 1.47 QUAL	Please describe the benefits you think the study has brought. Note: if no benefits seen in Question above – leave empty.	Type the response here.	
B2 - 1.48	Has the study brought any problems to the communities that you represent?	YES	
	, , , , , , , , , , , , , , , , , , , ,	NO (SKIP B2-1.49)	
		NOT YET (SKIP B2-1.50)	
		DON'T KNOW (SKIP B2-1.50)	

B2 - 1.49 QUAL	Please describe the problems you think the study has brought to this community.	Type the response here.	
B2 - 1.50	Has the study brought any problems to since the beginning of this study do	YES	
	you see changes being made to the way in which the study is conducted	NO (SKIP B2-1.51)	
	based on the feedback from the CAB given during advisory meetings?	DON'T KNOW	
B2 - 1.51 QUAL	If yes - can you list 1 to 3 changes you have seen the research make – based	1)	
, Q0/12	on the feedback that you or someone else in the CAB/CAG have given.	2)	
	3.00 m and 3.12, 5.10 mand g.10 m	3)	
B2 - 1.52	How difficult or easy is it to reach someone on the research team if you	Very Easy	
	have questions/concerns/suggestions you wish to share about the research	Easy	
	trial?	Difficult	
		Very Difficult	
		I don't know - never tried	
B2 - 1.53	If you have suggestions or advice for the study how would you go about	I would call /sms the liaison person or the research hotline – I have their phone number!	
	letting the research team know?	2) I would visit the community liaisons or research representative—I know where to go!	
		3) I would write a letter or email – I know where to send it!	
		4) I would mention this at the next CAB/CAG meeting – the meeting is scheduled!	
		5) I cannot – there is no way to reach them	
		6) I don't know what I would do – I don't have a plan/have not thought about this.	
		7) OTHER	
B2 - 1.54 QUAL	Please share with me any activities that the CAB carries out independently in the communities to support the	The CAB/CAG does not carry out activities in the community to support the research	
	research process?	Type the response here.	
B2 - 1.55	Time Interview Ended	□□HOUR □□MINUTE	
B2 - 1.56 QUAL	Observations – Comments Note down any further comments or imp	ressions and any lessons learned that require further follow up	or sharing.
	Observation 1	Any Follow up required	
	Observation 1	Any Follow up required	
	Observation 1	Any Follow up required	
	Observation 1	Any Follow up required	

Tools - SET B3

Broader Stakeholder Interview

When to complete

Monthly and Quarterly.

Target

 Broader Stakeholders - these include non-governmental organisations (NGOs), local health department directors, managers or policy makers, politicians, local media and medical professionals. Be reminded that this interview is not targeting community stakeholders.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 per month, considering all the relevant locations or zones represented in your trials' catchment area or as seen appropriate by your team.
- This will spur you on to actively reach out to new stakeholders every month.
- The more committed you are to scheduling key informant interviews with a wide array of community stakeholders
 and enquiring about their experience or lack of experience with your unit or trial, means that over time you will have a
 rich data set which will have more value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

• ½ hour.

TOOL B3 - BROADER STAKEHOLDER INTERVIEW

SECTION 1: GENERA	SECTION 1: GENERAL INFORMATION				
B3 - 1.0	INTERVIEW NUMBER				
B3 - 1.1	NAME OF RESEARCH TRIAL PROTOCOL/SUB-STUDY NUMBER				
B3 - 1.2	NAME OF LOCATION OR RESEARCH SITE				
B3 - 1.3	DATE OF INTERVIEW	DAY MONTH DDD YEAR			
B3 - 1.4	NAME OF INTERVIEWER				
B3 - 1.5	TIME INTERVIEW STARTED	□□HOUR □□MINUTE			

Preamble: Note to interviewer: Depending on your institutions rules, you may need to develop a consent form. Note — that this is a monitoring and evaluation tool and not a research tool.

Hello — I am the community liaison officer/manager for this research unit. To be sure that we are communicating and engaging with the different stakeholders properly around our studies, we would like to speak to you to find out more about how you have been reached by this study. I have a few questions to ask you and request that you be completely honest in your reply. We need to hear what you know about these studies and how you were reached. This will help to make us better at effectively engaging with various stakeholders around the clinical research trials we are conducting. Thank you for your time.

SECTION 2: INTERVI	EW		
B3 - 1.6	Mark the sex of the interviewee	Male	
		Female	
B3 - 1.7	What is the highest level of schooling you have completed?	I never attended school	
		I did part of Primary – incomplete	
		I completed Primary	
		I did part of Secondary - incomplete	
		I completed Secondary	
		I attended College	
		I attended University - Tertiary	
B3 - 1.8	Mark the kind of broader stakeholder this interviewee represents. Note: You may not need to ask this question	Write your response and then match your response to a category below there is no match to your response, choose other	– if
	if you can establish the answer on your own.	NOTE – Do not use this questionnaire if the interviewee is a TRIAL PARTICIPANT(use C1), or a PROSPECTIVE TRIAL PARTICIPANT (use C2) or a CAB MEMBER (use B2)	
		LOCAL POLICY MAKER	
		LOCAL LEGAL EXPERT/LAWYER ETC.	
		MEDIA PERSONNEL/JOURNALISTS	
		NON GOVERNMENTAL ORGANISATION	
		LOCAL HEALTH DEPARTMENT MANAGER OR DIRECTOR	
		LOCAL BUSINESS	
		Other (specify)	

B3 - 1.9	Apart from the CAB have you met to Do you know of or have you heard	YES				l
	of the research unit I represent as a community liaison officer/manager?	NO				
B3 - 1.10 QUAL	If you know - please share with me, what you think this organization/institute does in your community?	Type your response and then match your response to a category be match to your response, choose other.	elow :	– if th	nere is	s no
		POSTCODE – Choose all that apply.				
		I don't know what your organisation/group/Institute does (NO question above)	to			
		Your organisation treats adults/or children who are sick				
		Your organisation teaches/trains about health related issues				l
		Your organisation conducts health related (TB/HIV) prevention treatment research	/			
		Other (specify)				
If this persor	n does not know what the research or	ganisation does – please provide a thorough briefing at t	his p	oint		
B3 - 1.11	This organization works through	YES				
	clinics/health facilities to reach people - do you know where any of the research clinics are located?	NO				
B3 - 1.12	If yes, which facilities do you know about?					
	about?	Note: if the respondent does not know about the research sites or of where the research sites are located — you may need to elaborate can tell you where she or he lives in relation to one of the research	so the	e resp		ent
B3- 1.13	How well known is the organization	Very well known throughout my community				
	that is conducting the study in the community that you represent?	Well known in trial sites or around research clinics only				
		Only known by small groups of people				ı
		In general not known by people I mingle with				l
		I can't answer – as I don't know about the work that this organization is doing/have never heard about this organisation	n			
		List of studies – indicated in Setup	S1	S2	S3	S4
B3- 1.14	How well known do you think these studies are in the communities being	I don't know how well known this specific study is				
	targeted?	The specific study is very well known throughout the target communities				
	Note: list all the studies underway that you are responsible for as CLO	The specific study is only known by small groups of people				
	are responsible for all one	In general the specific study is not known by anyone apart from trial participants				
		The specific study is only known by health staff who have been oriented to the study				
		The specific study is only known by health staff who have been oriented to the study AND trial participants				
		I can't answer – as I don't know about this specific study				
B3 - 1.15 QUAL	This organisation carries out clinical research to improve the health of populations. Can you share anything you know about the research that this organisation conducts?	Write the response here. I have never heard about the organisation or this specific				
		research (Skip to B3 – 2.28)		L	_	

			T = .			
		List of studies – indicated in Setup	S1	S2	S2	S4
B3 - 1.16	How well do you think you understand the purpose of these research studies?	I know nothing about this research				
		I understand this trial very well – I have no questions				
		I understand their trial but I still have a few questions				
		I do not understand this trial — I have many questions				
		List of studies – indicated in Setup	S1	S2	S2	S4
B3 - 1.17	How involved/engaged/occupied are	Never				
	you with the work /research – how often do you do something to do with	Every day				
	this study?	Every week at least once				
		Every month at least once				
		Every 3 months at least once				
		At least twice a year				
		Other (specify)				
		List of studies – indicated in Setup	S1	S2	S3	S4
B3 - 1.18	Would you like to be more or less	MORE INVOLVED				
	involved in these clinical trials?	THE SAME INVOLVEMENT				
		LESS INVOLVED				
		INDIFFERENT/DON'T CARE/DON'T KNOW ABOUT IT				
B3 - 1.19 QUAL	Can you explain why you feel this way (referring to response above) and how you imagine, in your position you could support or be more involved with this research work?	Write the response here.				
B3 - 1.20	In general, are you very satisfied, satisfied, unsatisfied, very satisfied or	I have never heard about this research				
	indifferent about the way this research	Indifferent/Don't care				
	institutions consults with you as a community stakeholder?	Unsatisfied				
		Satisfied				
		Very Satisfied				
B3 - 1.21 QUAL	Please tell me why you feel this way (as described in the above question)?	Write the response here.				
B3 - 1.22	Have you ever made suggestions to the	YES		Γ		
	researchers/research staff about things they can do or change in relation to	NO (Skip to B3 – 1.24)				
	any of the trials underway?	NO because I have never heard of these trials (Skip to B3 – 1.24)				
B2 - 1.23 QUAL	Please share any suggestions on how things could be changed to improve the way the trials are run in order to improve the relationship with the stakeholders, including health personnel or policy makers?	Write the response here.				

B3 - 1.24	Are you aware of any negative messages about this study circulating	YES	
	3?	NO (SKIP B3 - 1.26)	
		Not applicable as have never heard of this study before today (SKIP B3 - 1.26)	
B3 - 1.25 QUAL	Can you share any of the negative messages/rumours you may have heard about this study?	Write the response here.	
B3 - 1.26	Have you been aware of any positive messages about this study circulating	YES	
	in your community?	NO	
		Not applicable - as never heard of this study before today	
B3 - 1.27 QUAL	Can you share any of the positive messages you may have heard about this study?	Write the response here.	
B3 - 1.28	Over the past 6 months, how would you rate the strength of your or your departments' engagement with these various research projects?	Very Strong We are involved in all (90 - 100%) aspects of the research, from planning through dissemination of the research.	
		Strong We are involved in most (710 to 89%) aspects of the research but no necessarily all development and planning.	
		Medium We are involved in about 60 to 70% of the research process.	
		Weak We are involved in very few aspects (40 - 59%) of the research activities.	
		Very Weak We are involved in less than 40% of the research activities.	
		I don't know – Not in a position to judge	
		List of studies – indicated in Setup	S1 S2 S3 S4
B3 - 1.29	How did you first hear about this/these research studies?	I have never heard about any of these research studies	
		I heard about this research through a colleague	
		I heard about this research through a committee meeting	
		I heard about this research through the health department	
		I heard about this research through the radio/TV/ newspaper/posters/flyers	
		I heard about this research while at a health event	
		I heard about this research while at a health training	
		I was visited by the study reps at my place of work	
		I was informed by our coordinator/supervisor at work	
		I was informed when someone from the research unit visited my organisation/company/resource	
		I was informed through a conference/briefing workshop	
		Other (specify)	

		List of studies – indicated in Setup	S1	S2	S3	S4
B3 - 1.30	How often do you receive an update about this research?	I never receive updates				
	about the rootator.	I receive updates – irregularly/from time to time				
		I receive updates every day				
		I receive updates every week				
	I receive updates every two weeks					
		I receive updates every month				
		I receive updates every two months				
		I receive updates every 3 months				
		I receive updates every 4 – 6 months				
		I receive updates once a year				
		I receive updates every few years				
		Other (specify)				

B3 - 1.31 QUAL	Which groups of people with whom you work do you think	response, choose other.	nen match your response to a category below – if there is no match	to your
	should know about this research?	POSTCODE -select best op		1
	uns research?	INDIVIDUAL RESIDENTS I	IN THE TARGET AREA	
		PEOPLE AFFECTED BY TH	HE DISEASE BEING STUDIED	
		PEOPLE WHO WILL BENE	FIT FROM THE INTERVENTION BEING STUDIED	
		PEOPLE WHO MAY BE EL	IGIBLE TO PARTICIPATE IN THE STUDY	
		HEALTH ADVOCATE or AC	CTIVIST	
		COMMUNITY BASED ORG	GANISATION STAFF	
		NON GOVERNMENTAL OF	RGANISATION STAFF	
		SCHOOL TEACHERS		
		STUDENTS/CHILDREN		
		LOCAL HEALTH FACILITY	STAFF/HEALTH WORKERS /COMMUNITY HEALTH WORKERS	
		LOCAL FAITH BASED LEA	ADERS	
		LOCAL LEADERSHIP – GO	OVERNMENT OR ELECTED	
		LOCAL LEADERSHIP – TR	RADITIONAL	
		LOCAL – DEPARTMENT O	OF HEALTH STAFF/MANAGERS	
		MEDIA PERSONNEL/JOU	RNALISTS	
		LOCAL BUSINESS OWNE	RS/BUSINESSES	
		LEGAL SPECIALISTS		
		LOCAL POLICY MAKERS		
		Other (specify)		
B3 - 1.32	Do you know a specific the research team or at		YES	
	whom you could speak		NO	
B3 - 1.33	Do you know about the	CAB – community nity Advisory Group/CR –	YES	
	community representat	ives (please use a term	NO (SKIP B3 - 1.35)	
B3 - 1.34	If you know about the C	Community Advisory	Write the response here.	
QUAL	Board please describe v purpose is?	what you think its		
B3 - 1.35	Time Interview Ended		□□HOUR □□MINUTE	
B3 - 1.36 QUAL	Observations – Comme	nts – Issues for Follow up		
	Observation 1		Any Follow up required	
				_
	Observation 2		Any Follow up required	
	Observation 3		Any Follow up required	
	Observation 4		Any Follow up required	

Tools - SET C1

Trial Participant Interview

When to complete

Monthly and Quarterly.

Target

• Enrolled Trial Participants at any stage of the trial.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 trial participant interviews per month, factoring all the relevant locations or zones represented in your trials' catchment area or as seen appropriate by your team.
- This will spur you on to actively reach out to trial participants each month and gauge their levels of engagement.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

• ½ hour.

TOOL C1 - TRIAL PARTICIPANT INTERVIEW

SECTION 1: GENERA	SECTION 1: GENERAL INFORMATION				
C1 - 1.0	INTERVIEW NUMBER				
C1 - 1.1	NAME OF RESEARCH TRIAL				
C1 - 1.2	PROTOCOL/SUB-STUDY NUMBER				
C1 - 1.3	NAME OF LOCATION OR RESEARCH SITE				
C1 - 1.4	DATE OF INTERVIEW	Day Day Month DDD year			
C1 - 1.5	NAME OF INTERVIEWER				
C1 - 1.6	TIME INTERVIEW STARTED	□□HOUR □□MINUTE			

Preamble: Note to interviewer: Depending on your institutions rules, you may need to develop a consent form. Note — that this is a monitoring and evaluation tool and not a research tool.

Hello – I am the community liaison officer/manager for this research unit. To be sure that we are communicating and engaging with the different stakeholders properly around our studies, we would like to speak to you to find out more about how you have been reached by this study. I have a few questions to ask you and request that you be completely honest in your reply. We need to hear what you know about these studies and how you were reached. This will help to make us better at effectively engaging with various stakeholders around the clinical research trials we are conducting. Thank you for your time.

SECTION 2: INTERVI	EW		
C1 - 1.7	Mark the sex of the interviewee	Male	
		Female	
C1 - 1.8	What is the highest level of schooling you have completed?	I never attended school	
		I did part of Primary – incomplete	
		I completed Primary	
		I did part of Secondary - incomplete	
		I completed Secondary	
		I attended College	
		I attended University - Tertiary	
C1 - 1.9	What did you come to the clinic for today?	A scheduled interview	
		Scheduled Study Visit	
		Unscheduled Medical Visit (illness, concern)	
		Other	
C1 - 1.10	Did you get the services you came for today?	YES	
		NO	
		NOT YET/ I have not been seen yet	

C1 - 1.11 QUAL	How do you feel about the overall quality of the services you got today? Once you have written the response you will be asked to select the postcode options that best match the answer.	Write the response here. Once you have written the response you will be asked to select the postco that best match the answer	de options
		POSTCODE	
		Very Good Services	
		Good Services	
		Poor Services	
		Very Poor Services	
		NO	
C1 - 1.12	Are you aware that you are enrolled in	Yes	
	a research study/clinical trial?	No (INTERRUPT INTERVIEW)	
C1 - 1.13 QUAL	Please describe how you first heard about this study or how were you first contacted by the study?	Write the response here. Once you have written the response you will be asked to select the postco that best match the answer	de options
		POSTCODE	
		During a home visit	
		Through a friend	
		Through leaders in my community	
		At the hospital/health centre/dispensary and then they referred me for screening	
		During a community meeting	
		Through the radio/television	
		Through a poster	
		Other (specify)	
C1 - 1.14	At the moment, how well do you think	I understand this study very well – I have no questions	
	you understand this research in which you are enrolled and do you have	I understand this study – I still have a few questions	
	questions about the study?	I do not understand this study – I have many questions	
		I know nothing about this study	
C1 - 1.15	Where do you live relative to one of the	5 – 15 minutes on foot	
	research clinics? Note: if the respondent does not know	16 – 30 minutes by foot	
	about the research sites or does not know where the research sites are located – you	>30 minutes by foot	
	may need to elaborate.	5 – 15 minutes in a bus/taxi/daladala/matatu	
		16 – 30 minutes in a bus/taxi/daladala/matatu	
		>30 minutes in a bus/taxi/daladala/matatu	

C1 - 1.16	How well known is this study in the	Very well known throughout my community	
	community where you live?	Well known around the research clinics only	
		Only known by small groups of people within my community	
		Only known by patients enrolled in the research or screened patients	
		Not known by people in my community	
		Other	
C1 - 1.17	Do you think it's important for the	YES	
	study to inform certain people in the community while it is conducting	NO (SKIP)	
	research in or near your community?	DON'T KNOW – NOT SURE	
C1 - 1.18 QUAL	Please share with me whom you think should know more about this study in your community?	Write the response here. Once you have written the response you will be asked to select the postco that best match the answer	de options
		POSTCODE - CHOOSE MANY	
		INDIVIDUAL RESIDENT IN THE TARGET AREA	
		MY FRIENDS AND FAMILY OF FRIENDS AND FAMILIES OF PARTICIPANTS	
		PEOPLE IN NEED OF THE TREATMENT/CARE/PREVENTION	
		ADVOCATE or ACTIVIST	
		COMMUNITY BASED ORGANISATION STAFF	
		NON GOVERNMENTAL ORGANISATION STAFF	
		SCHOOL TEACHER	
		YOUTH WORKER	
		STUDENTS IN SCHOOLS	
		LOCAL HEALTH FACILITY STAFF	
		TRADITIONAL HEALER	
		LOCAL FAITH BASED LEADER	
		LOCAL LEADERSHIP – GOVERNMENT OR ELECTED	
		LOCAL LEADERSHIP - TRADITIONAL	
		COMMUNITY HEALTH WORKER	
		MEDIA PERSONNEL/JOURNALISTS	
		LOCAL BUSINESS OWNERS	
		LOCAL POLICY MAKERS	
		LOCAL BUSINESS	
		LEGAL EXPERT	
		Other (specify)	
C1 - 1.19 QUAL	Please share with me why you feel these people should be informed?	Write the response here.	
C1 - 1.20 QUAL	Please can you tell me about any positive messages you have heard in the community about this study?	Write the response here.	
		I have not heard any positive messages	

C1 - 1.21 QUAL	Please can you tell me about any negative messages or rumours you may have heard in the community about this study?	Type the response here.				
		I have not heard any negative messages				
C1 - 1.22	Is there anything that you do not like	YES				
	about this study or something that worries you about the research?	NO (SKIP C1 - 1)				
C1 - 1.23 QUAL	What do you not like or what worries you about participation in this study?	Type the response here.				
C1 - 1.24	What were the 3 most important reasons that made you willing to	Previous experience or reputation of research unit				
	participate in this study? Free medical assistance/treatment for participants					
	(Probe anything else-tick as many as possible)	Better treatment/quality health care services for participants				
		Transport to and from the clinic				
		The study was well explained with information that convinced me to participate				
		The views/influences of key people in the community convinced me to participate				
		The intervention/drug/vaccine is beneficial for my wellbeing/future				
		I wanted to test/check the rumours				
		Availability of food at the clinic				
		This research will benefit other people				
		Others (specify)				
C1 - 1.25	How do you feel about the decision you made to be involved in this study?	Нарру				
		Not happy				
		Indifferent/Don't Care				
C1 - 1.26	How much do you trust this research study and the research team?	I trust the research team				
		I don't trust the research team				
		I am not sure how I feel				
C1 - 1.27 QUAL	Please can you explain to me in your own words why you feel this way (I trust the research team, I don't trust the research team; I am not sure – my opinion changes)	Type the response here.				
C1 - 1.28	Since joining the study, have you experienced any differences in how	YES				
	people treat you/your child/family?	NO				

C1 - 1.29	What differences have you experienced?		I have not experienced any differences (NO above)						
	ехрененсец:		We	/I am segregate	ed or excluded f	rom community	activities		
			Oui	Our/my family treats me differently					
			Gov	vernment healtl	h facility staff tr	eat me/ us differ	ently		
				ose who are not ate to me/us dit		re envious/jealou	is and		
			Oth	ner					
C1 - 1.30	Do you know about the CAB Community Advisory Board?		ΥE	S					
	Community Advisory Board:		NO	(SKIP B1 - 1.29)				
C1 - 1.31 QUAL	If you know about the CAG/O please describe what you th purpose is?		Тур	e the response	here.				
C1 - 1.32	Do you remember the inform consent process before you				YES				
	concern process percie you	om onou.	NO						
C1 - 1.33 QUAL	Can you recall the process a describe the informed conse to me as you remember it?		Тур	e the response	here.				
C1 - 1.34	If you have questions or con about something to do with	your	I would call /sms the contact person – I have their phone number!						
	participation (or participatio child) in this research trial –	how would	2) I would visit the contact person – I know where to go!				e to go!		
	you inform the research tea	m?	 I would go to the clinic early before my next scheduled visit. 						
			4) I would wait until the next scheduled clinic visit.						
			5) I would talk to the Chief or Local Leader.						
			6) I would go to my local health centre.						
			7) I would talk to a friend or neighbour.						
			I would call/contact/visit another research volunteer/ participant.				unteer/		
			9)	l would keep i	t to myself.				
			10)	I don't know v not thought at		– I don't have a p	olan/have		
C1 - 1.35	How many months have	0-3 months		4-6 months	7-12 months	13-24 months	2-3 years		>3 years
	you been enrolled in this study?								
C1 - 1.36	Time Interview Ended	ПП П ног	JR [MINUTE					
C1 - 1.37 QUAL	Observations Note down any further comme state them	ents or impress	sions	shared by the in	nterviewee — reco	rding their answei	rs word for v	vord e	exactly as they

Tools - SET C2

Prospective Trial Participant Interview

When to complete

Monthly and Quarterly.

Target

 Prospective Trial Participants who have been briefed on the trial and have been screened but have not yet qualified for enrolment.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 per month, considering all the relevant locations or zones represented in your trials' catchment area or as seen appropriate by your team.
- This will spur you on to actively reach out to new stakeholders every month.
- The more committed you are to scheduling key informant interviews with a wide array of community stakeholders and enquiring about their experience or lack of experience with your unit or trial, means that over time you will have a rich data set which will have more value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

• ½ hour.

TOOL C2 - PROSPECTIVE VOLUNTEER - POST SCREENING INTERVIEW

SECTION 1: GENERA	SECTION 1: GENERAL INFORMATION				
C2 - 1.0	INTERVIEW NUMBER				
C2 - 1.1	NAME OF RESEARCH TRIAL				
C2 - 1.2	PROTOCOL/SUB-STUDY NUMBER				
C2 - 1.3	NAME OF LOCATION OR RESEARCH SITE				
C2 - 1.4	DATE OF INTERVIEW	DDAY DMONTH DDD YEAR			
C2 - 1.5	NAME OF INTERVIEWER				
C2 - 1.6	TIME INTERVIEW STARTED	□□HOUR □□MINUTE			

Preamble: Note to interviewer: Depending on your institutions rules, you may need to develop a consent form. Note — that this is a monitoring and evaluation tool and not a research tool.

Hello — I am the community liaison officer/manager for this research unit. To be sure that we are communicating and engaging with the different stakeholders properly around our studies, we would like to speak to you to find out more about how you have been reached by this study. I have a few questions to ask you and request that you be completely honest in your reply. We need to hear what you know about these studies and how you were reached. This will help to make us better at effectively engaging with various stakeholders around the clinical research trials we are conducting. Thank you for your time.

SECTION 2: INTERVI	EW		
C2 - 1.7	Mark the sex of the interviewee	Male	
		Female	
C2 - 1.8	What is the highest level of schooling you have completed?	I never attended school	
		I did part of Primary – incomplete	
		I completed Primary	
		I did part of Secondary - incomplete	
		I completed Secondary	
		I attended College	
		I attended University - Tertiary	
C2 - 1.9	What did you come to the clinic for today?	Enquiry about enrolling in study	
		Eligibility/Screening for this study	
		Informed Consent – Pre –Enrolment	
		A scheduled interview	
		Scheduled Study Visit for enrolled volunteer (you should complete form C3)	
		Medical Visit – illness, concern (if respondent not screened for study – end interview now)	
		Other (specify)	

C2 - 1.10	Did you get the services you came for today?					
	toudy:	NO				
C2 - 1.11	How do you feel about the overall quality of the services you got today?	Type the response here. Once you have written the response you will be asked to select the post best match the answer.	options that			
		POSTCODE				
		Very Good Services				
		Good Services				
		Poor Services				
		Very Poor Services				
C2 - 1.12	Have you heard about this research	YES				
	study on conducted by?	NO				
C2 - 1.13	How did you first hear about this study	I don't know about any study				
	or how were you first contacted by the study?	During a home visit				
		Through a friend				
	Through leaders in my community At the hospital/health centre/dispensary					
		At the hospital/health centre/dispensary				
		At the hospital/health centre/dispensary and then they referred me for screening				
		During a community meeting				
		Through the radio/television				
		Through a poster				
		Other (specify)				
C2 - 1.14 QUAL	What information have you received about this research study and its purpose?	Type the response here.				
		I have never heard about this study				
C2 - 1.15	Where do you live relative to one of the research clinics or relative to this	5 – 15 minutes on foot				
	research clinic where you are now?	16 – 30 minutes by foot				
		>30 minutes by foot				
		5 – 15 minutes in a bus/taxi/daladala/matatu				
		16 – 30 minutes in a bus/taxi/daladala/matatu				
		>30 minutes in a bus/taxi/daladala/matatu				
C2 - 1.16	Does this research study offer any other services to the community that	I don't know				
	you know of?	Treating adults/or children who are sick				
		Assisting the community in other ways				
		Teaching local community about health related issues				
		Conducting health related research				
		Other (specify)				

C2 - 1.17	How well known is this study in the	YES	
02 - 1.17	community where you live?	NO NO	
C2 - 1.18	Do you think it's important for the	YES	
UZ - 1.10	Do you think it's important for the study to inform certain people in the		
	community while it is conducting research in or near your community?	NO	
C2 - 1.19 QUAL	Please share with me whom you think should know more about this study in your community?	Type the response here. Once you have written the response you will be asked to select the post best match the answer.	options that
		POSTCODE	
		INDIVIDUAL RESIDENT IN THE TARGET AREA	
		MY FRIENDS AND FAMILY OF FRIENDS AND FAMILIES OF PARTICIPANTS	
		PEOPLE IN NEED OF THE TREATMENT/CARE/PREVENTION	
		ADVOCATE or ACTIVIST	
		COMMUNITY BASED ORGANISATION STAFF	
		NON GOVERNMENTAL ORGANISATION STAFF	
		SCHOOL TEACHER	
		YOUTH WORKER	
		STUDENTS IN SCHOOLS	
		LOCAL HEALTH FACILITY STAFF	
		TRADITIONAL HEALER	
		LOCAL FAITH BASED LEADER	
		LOCAL LEADERSHIP – GOVERNMENT OR ELECTED	
		LOCAL LEADERSHIP - TRADITIONAL	
		COMMUNITY HEALTH WORKER	
		MEDIA PERSONNEL/JOURNALISTS	
		LOCAL BUSINESS OWNERS	
		LOCAL POLICY MAKERS	
		LOCAL BUSINESS	
		LEGAL EXPERT	
		OTHER (specify)	
C2 - 1.20 QUAL	Please share with me why you feel these people should be informed?	Type the response here.	
C2 - 1.21 QUAL	Please can you tell me about any positive messages you have heard in the community about this study?	Type the response here.	
		I have not heard any positive messages	
C2 - 1.22 QUAL	Please can you tell me about any negative messages or rumours you may have heard in the community about this study?	Type the response here.	
		I have not heard any positive messages	
C2 - 1.23	Is there anything that you do not like about this study or something that	YES	
	worries you about the trial?	NO (SKIP C2 - 1.26)	

C2 - 1.24 QUAL	What do you not like or what worries you about participating in this study?	Write the response word for word					
	Only if the respondent is not forthcoming						
	you can use some of these as probes; • Potential side effects - drug/vaccine						
	Potential Risks of the intervention - drug/vaccine						
	Discomfort of Procedures - e.g. blood taking						
	My health may suffer The time it takes - Inconvenience						
	Travel Distance						
	CostStigma/Rumours						
C2 - 1.25	What are the 3 most important reasons why you would consider volunteering for this study)?	Type the response here. Once you have written the response you will be asked to select the post best match the answer.	options that				
	(Probe anything else-tick as many as possible)						
		POSTCODE					
		Previous experience or reputation of research unit					
		Free medical assistance/treatment for participants					
		Better treatment/health care services for participants					
		The study was well explained with details that convinced me					
		The views/influences of key people in the community					
		The intervention/drug/vaccine is beneficial					
		I wanted to test/check rumours					
		Participants get free transport to the facility					
		This research will benefit other people					
		Participants get reimbursements for time and travel					
		The research leads to better health					
		Others (specify)					
C2 - 1.26	After todays' visit are you considering volunteering for this research study?	YES					
	volunteering for this research study:	NO					
		Don't Know					
C2 - 1.27	Time Interview Ended	HOUR MINUTE					
C2 - 1.28	Observations						
QUAL	(Note down any further comments or impercently as they state them)	pressions shared by the interviewee – recording their answers word	for word				
	-						

Tools - SET D1

SELF ASSESSMENT - For COMMUNITY ENGAGEMENT MANAGER or CLO

When to complete

• Every 6 months.

Target

• To be completed by the persons responsible for community engagement (manager/liaison) and the information entered directly into database during collection/completion. If this is the first self-assessment, you can reflect on the life of the various trials to date, if this is the second assessment, you should reflect on the past 4-6 months only.

Number to complete

- There is no defined sample size however we suggest that you conduct a minimum of 2 self assessments per year and that all your CLO's and staff in the CSE department do so every 6 months.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

½ hour.

TOOL D1 - SELF ASSESSMENT For COMMUNITY ENGAGEMENT MANAGER or COMMUNITY LIAISON OFFICER

SECTION 1: GENER	AL INFORMATION							
D1 - 1.0	SELF ASSESSMENT NUMBER							
D1 - 1.1	NAME OF RESEARCH TRIAL							
D1 - 1.2	NAME OF LOCATION OR RESEARCH SITE							
D1 - 1.3	DATE OF SELF-ASSESSMENT	Day Day Month D]	ÆAR				
D1 - 1.4	TIME SELF ASSESSMENT STARTED	HOUR MINUTE						
SECTION 2: SELF A	SSESSMENT							
D1 - 1.5	What is your role and title in this research trial?	Community Engagement Manager – I	n charge					
	that.	Community Liaison – In charge						
		Community Liaison – Junior						
		Other (specify)						
D1 - 1.6	How long have you been in this position?	Less than 1 year						
		Over 1 year – under 2 years						
		Over 2 year – under 3 years						
		Over 3 years						
			S1	S2	S3	S4		
D1 - 1.7	For how long have you been involved in the various trials in which you are	I am not involved in this particular study as a CLO						
	involved as a Community Engagement Manager?	From the initial stages of planning/ protocol development						
		From the stages of implementation/ Initiation of recruitment						
		Joined once the trial was already well underway						
		Other - None of these apply						
D1 - 1.8	Reflecting on the past 6 months of the	Very well known throughout						
	trial, in your opinion how well known is your research organisation in the im-	Well known around trial sites						
	mediate local communities where you are conducting your clinical trial?	Only known by small groups of people						
	ooridating your omnour than	Only known by research participants a						
		In general not known						
		I don't know						
		Other (specify)						
D1 - 1.9	Reflecting on the past 6 months, how well do you think the communities in	Understand very well						
	which you are conducting your clinical	Understand						
	trial understand the purpose of the study?	P Don't Understand						
		I don't know						
D1 - 1.10	Reflecting on the past 6 months, how	I don't know – I am not aware – We h	nave not a	ssessed				
	engaged is your CAB in issues relating to your clinical trial (s)?	Very engaged						
		Engaged						
		Not engaged						
		Indifferent		_				

D1 - 1.11 QUAL	Reflecting on the past 6 months which mechanisms have you as the community stakeholder engagement team used to inform or consult community stakeholders?	Write your response and then match your response match to your response, choose other	to a category	y below — if there is no
	Write your answer and then select the	POSTCODE		
	relevant postcode options if applicable.			RATE HOW OFTEN YOU ADOPT THIS APPROACH 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT 3 = ALWAYS
		I don't know – I am not aware		
		CAB & CAB Activities only		
		Groups of Community Representatives (non CAB)		
		Community Public Meetings Gatherings/Dialogues		
		CBOs, FBOs, or other community networks		
		Face to face discussions/ home visits		
		Interactions at hospitals and health facilities or clinics		
		Dissemination of IEC materials		
		Press/radio coverage		
		Outreach education efforts		
		Theatre/music/sport		
		National networks and conferences		
		Briefings/meetings/consultations		
		Other (specify)		
D1 - 1.12 QUAL	Reflecting on the past 6 months, which mechanisms have you as the community engagement team used to consult with broader stakeholders – beyond the communities where the trial is underway?	Write your response and then match your response match to your response, choose other POSTCODE	to a category	y below — if there is no
	Write your answer and then select the		Select if	RATE HOW OFTEN
	relevant postcode options if applicable.		relevant	YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT 3 = ALWAYS
		Through local leadership		
		Through the health facility		
		Through hosting events – theatre, concerts		
		Through small meetings – focus groups		
		Through community meetings		
		Through schools		

		Face to Face Discussions / Ho	ome visits				
		Through posters and flyers					
		Through radio and newspape	r				
		Through CAB					
		Through a CBO					
		Through NGO advisory Group					
		Through IEC materials					
		Outreach efforts					
		Through theatre/music/sport					
		None of the above					
		Other (specify)					
D1 - 1.13	Reflecting on the past 6 months to 1 year which stakeholders (community or broader as per definitions in the manual) have been involved in any of the following activities relating to this trial?					BSH	None/ Neither/ Don't Know
	Formative research activities – discussions before the research begins						
	Stakeholder advisory plans – discussions to plan how all stakeholders and gate keepers are engaged in the study						
	Stakeholder education plan – discus community and broader stakeholders	ssions to plan how to sensitize and infor (as per definition at start)	m				
	Communication plans – discussion of communities for trial recruitment and	on how to communicate and reach out t enrolment.	o target				
	Issues management plan – discussion on how to address problems that may arise in the community in relation to the research study						
	Site selection – discussion around w	hich research sites to select and why					
	Protocol development – discussion around the development of the research plan and approach						
	Informed consent process - discussion around the informed consent process and forms for prospective trial participants						
	Access to care and treatment for trial participants - discussion about what services trial participants may or may not receive while enrolled						
	Recruitment and retention and follo support trial participants	wwwp-discussion about how to access	s, retain and				
	Trial participant exit from trial - dis trial when the trial ends	cussion on how to transition participant	s out of the				
	Results dissemination - discussion community stakeholders	on research results and how to inform t	he				
	Post-trial access to care and treatn after the research is complete	nent – discussion on services for trial p	articipants				
D1 - 1.14	In your assessment, over the past 6 months, how well is		S1	S2		S3	S4
	your engagement work on this trial aligned with GPP – good	Very well aligned – excellent					
	participatory practice guidelines?	Aligned – good					
		Poorly aligned					
		Not aligned					
		I don't know – Not aware – What is GPP?					

D1 - 1.15 QUAL	Reflecting on the past 6 months what has been the predominant focus of your engagement with the community stakeholders (CSH) and broader stakeholders (BSH)?	Type your response an match to your respons		sponse to a categor	y below — if the	ere is no
	otationalia (2011)	POSTCODE				
					CSH	BSH
		ADHERENCE ISSUES				
		COMMUNICATION PL				
		COMMUNITY ENTRY/	INTRO			
		CT/POST TRIAL ACCE	SS TO CARE			
		FOLLOW UP ISSUES				
		FORMATIVE WORK				
		INFORMED CONSENT	•			
		ISSUES MANAGEMEN	IT PLAN			
		MOBILIZATION/SENSI	ITIZATION/EDUCATION	N		
		PLANNING				
		POST TRIAL ACCESS				
		PROTOCOL DEVELOPI	MENT			
		PROTOCOL REVIEW				
		RECRUITMENT				
		RESOURCE IDENTIFIC	CATION			
		RESULTS DISSEMINA	TION			
		RETENTION ISSUES				
		ROLE CLARIFICATION				
		SITE SELECTION				
		STAKEHOLDER ADVIS	ORY PLAN			
		STAKEHOLDER EDUC	ATION PLAN			
		STUDY BRIEFING				
		STUDY INFO UPDATE	S			
		TRAINING				
		UPDATE/FEEDBACK				
		OTHER (specify)				
D1 - 1.16 QUAL	Please write any key suggestions or any constructive solutions which you are aware the community stakeholders (can include the CAB), have made to	Write your response	here			
	any or all of your trials.	Did the trial act on these suggestions?	YES	NO	No suggest	ions made
		anoso suggestions.				
D1 - 1.17 QUAL	Please write any key suggestions or any constructive solutions which you are aware that any broader stakeholders have made to any or all of	Write your response	here			
	your trials.	Did the trial act on these suggestions?	YES	NO	No suggest	ions made
		these suggestions?				

D1 - 1.18 QUAL	If you have acted on suggestions in the past 6 months, please share those actions in detail. If you have not acted on suggestions, can you explain why you think no actions have been taken, as a result of	Write your response					
D1 - 1.19	stakeholder participation? Based on results, over the past 6	Very Important and essential					
	months how important has your stakeholder engagement programme	Important but not essential					
	been to the clinical trial operations?	Limited value					
		Not important					
		I don't know – there is no data to show value]	
D1 - 1.20 QUAL	Please give concrete examples of how the stakeholder engagement programme has directly benefited the trial over the past 6 months? Note – do not make sweeping statements without concrete evidence.	Write your response					
D1 - 1.21	On average, over the past 6 months, how often have you consulted		CSH	BSH	NSH	ISH	
	in person/directly with various stakeholders (SH)? CSH – community SH BSH – broader SH	Every day					
		Every week at least once					
		Every month at least once					
	NSH – national SH ISH – international SH	Every 3 months at least once					
		At least twice a year					
		Once a year					
		Not sure – very rarely					
		Never					
D1 - 1.22	Reflecting on the past 6 months, are you very satisfied, satisfied, unsure,		CSH	BSH	NSH	ISH	
	dissatisfied, very dissatisfied with your stakeholder engagement outputs?	Very Satisfied					
		Satisfied					
		Unsure					
		Dissatisfied					
		Very Dissatisfied					
D1 - 1.23 QUAL	Please give a examples that illustrate why you are very satisfied, satisfied, unsure, dissatisfied, dissatisfied with stakeholder engagement over the past 6 months.	Write your response					
D1 - 1.24	Over the past 6 months, how would you rate the strength of your research		S1	S2	S3	S4	
	projects' engagement with the stakeholders (for each of the trials underway	Very Strong The CSH or BSH is/are involved in all (90-100%) aspects of the research, from planning through dissemination of the research.					
	under way	Strong The CSH or BSH is/are involved in most (71-89%) aspects of the research but not necessarily all development and planning.					
		Medium The CSH or BSH is/are involved in about 60 to 70% of the research process.					
		Weak The CSH or BSH is/are involved in very few aspects (40-59%) of the research activities					

		Very Weak The CSH or BSH is/are involvactivities. I don't know – Not in							
D1 - 1.25	In the past 6 months (or life of trial as pe agreements with your community stakeh (Do not mention those already indicated	holders ORCABS? Be sure to upload this agreement at the			[
		,		I DON'T KNOW (SKIP D1 - 1.27)			[
	Note: if this is the first self-assessment, trial to date, if this is the second assessment 6 months only.	you can reflect on the nent, you should reflec	NO (SKIP D1 - 1.27)			[
D1 - 1.26	If yes - Please indicate the name(s) of the document(s). Also be sure to attach this document at the end of the self- assessment.								
D1 - 1.27	If yes, does this agreement with the	No agreement devel	No agreement developed/Or don't know if agreement developed						
	stakeholders address any or all of the following:	I don't know the con	tent of the aç	greement			[
participants? • Data ownership?	Roles & responsibilities of all	Ethics					[
		Roles & responsibilities of all participants			[
	Dispute resolution?Dissemination of results?	Data ownership			[
• DIS	- Dissemination of results:	Dispute resolution			[
		Dissemination of results			[
		Other (specify)			[
D1 - 1.28	Reflecting on the past 6 months, on average how often have you engaged	I don't know – I'm not involved							
	with stakeholders of any kind related to any of the trials? (excluding already	Every day							
	enrolled trial participants)	Every week at least once							
		Every month at least once Every 3 months at least once							
		-							
		At least twice a year I don't know							
		Other (specify)							
D1 - 1.29	Currently how many full or part time	Full T	ime		P	art Time	<u> </u>		
J. 1.20	staff are employed by the research unit to address community engagement?	Write No				te Numb			
D1 - 1.30	How much did the community	S1	S2		S3	.5	S4		
01 1.00	stakeholder engagement (CSE) programme spend in the past 6 months for CSE efforts for each of the trials you are involved in?	\$	\$	\$		5	34		
D1 - 1.31 QUAL	Can you share, in detail, what lessons you have learned about how to conduct CSE over the past 6 months?	Write your response		1					

D1 - 1.32	Over the past 6 months – as the CLO - how supported do you feel by	Very supported	
	the clinical research team and other members of the research team?	Supported	
	moniporo or ano roboaron toann.	Not supported	
		I don't know	
D1 - 1.33 QUAL	Why do you feel the way you have described above – not supported, supported or very supported?	Write your response	
D1 - 1.34	Reflecting on the past 6 months, can you rate your stakeholder engagement	Excellent - We are achieving our community engagement goals/on target with our work plan	
	efforts – how well are you achieving your goals?	Good – we are progressing well and steadily – we are nearly on target with our work plan	
		Average – we are achieving some of our targets, we are lagging behind on our targets	
		Poor – we are not achieving our goals and targets	
		I don't know	
D1 - 1.35 QUAL	Please comment in detail on your response above and suggest why this is the case?	Write your response	
D1 - 1.36	TIME SELF ASSESSMENT ENDED	HOUR MINUTE	
ADD ATTACHMENTS O	F DOCUMENTS – referred to in this self-as	sessment.	

Tools - SET D2

PRINCIPAL INVESTIGATOR or SENIOR RESEARCHER SELF ASSESSMENT

When to complete

• Every 6 months.

Target

- To be completed by the Principal Investigators (PIs) and Senior Researchers within your trial ideally each PI or Researcher should complete two or three self assessments during the course of a trial.
- If this is the first self-assessment, the PI or Senior Researcher can reflect on the life of the various trials to date, if this is the second assessment, you should reflect on the past 4-6 months only.

Number to complete

- There is no defined sample size however we suggest that an absolute minimum of 1 self-assessment every 6
 months. In the course of the trial every PI and Senior researcher should self-assess a least once, preferably once a
 year.
- This will engage the views of PIs and researchers more effectively.
- The more committed you are to scheduling time for these self-assessment the more likely you are to collect the reflective data from those running the trials that sheds light on how much they understand CSE efforts and their suggestions.
- Over time you will have a rich data set which will have great value in the long term.
- The richer your M&E Data will be and the greater the justification for your work and its potential impact on trial outcomes.

Key terms for this tool

Post Code: Coding is an analytical process in which both quantitative (such as questionnaires) and qualitative (such as narratives) data are categorised to facilitate analysis. In the case of these questionnaires, you are required to record the narrative of the respondent, word for word and then post code or select the applicable code that corresponds with the response.

Estimated Time

½ hour.

TOOL D2 – CAB - PRINCIPAL INVESTIGATOR or SENIOR RESEARCHER SELF-ADMINISTERED QUESTIONNAIRE

SECTION 1: GENERA	L INFORMATION		
D2 - 1.0	INTERVIEW NUMBER		
D2 - 1.1	NAME OF RESEARCH TRIAL		
D2 - 1.2	NAME OF LOCATION OR RESEARCH SITE		
D2 - 1.3	DATE OF INTERVIEW	DAY MONTH PAR	
D2 - 1.4	TIME INTERVIEW STARTED	□□HOUR □□MINUTE	
SECTION 2:			
D2 - 1.5	What is your position in this trial?	Principal Investigator – International	
		Senior Researcher – International	
		Principal Investigator – In country	
		Senior Researcher – In country	
		Other (specify)	
D2 - 1.6	How long have you been in this position?	Less than 1 year	
		Over 1 year – under 2 years	
		Over 2 year – under 3 years	
		Over 3 years	
D2 - 1.7	For how long have you been involved in this trial as a PI or Senior Researcher?	From the initial stages of planning/protocol development/ review	
		From the stages of implementation/Initiation of recruitment	
		Joined once the trial was already well underway	
		Other - None of these apply	
D2 - 1.8	Reflecting on the past 6 months of the trial - in your opinion how well known is	Very well known throughout	
	your research organisation/unit in the	Well known around trial sites	
	immediate local communities where you are conducting your clinical trial?	Only known by small groups of people	
		In general not known	
		I don't know – I am not involved	
		Other (specify)	
D2 - 1.9	Reflecting on the past 6 months (or longer if this is the first self-assessment	I don't know – I am not aware – I am not involved	
	you are completing), in your opinion, how	Very engaged	
	engaged is your CAB in issues relating to this clinical trial (s)?	Engaged	
	· · · · · · · · · · · · · · · · · · ·	Emerging Engagement – engagement is in early days	
		Not engaged	
		Indifferent	
D2 - 1.10 QUAL	Reflecting on the past 6 months which mechanisms has your research team including your stakeholder engagement team used to inform or consult community stakeholders within the communities where your trial is underway?	Write response here	

		POSTCODE				
	to inform or consult community stakeholders within the communities where your trial is underway?		Select if relevant	RATE HOW OFTEN YOU ADOPT THIS APPROACH 0 = NEVER		
	Write your answer and then select the relevant postcode options if applicable.			1 = OCCASIONAL 2 = FREQUENT 3 = ALWAYS		
		I don't know – I am not aware				
		CAB				
		Trial Participant Groups				
		Stakeholder meetings				
		Local events				
		Community Dialogues				
		Face to Face Discussions/Home Visits				
		Focus Group Discussions				
		Radio /Press/Media				
		NGO Advisory Groups				
		Theatre/Music/Sport events				
		Groups already established in the area				
		National Conferences				
		Other (specify)				
D2 - 1.11 QUAL	Reflecting on the past 6 months which mechanisms has your research team/ community engagement team used	Write your response here				
	to consult with broader stakeholders – beyond the immediate communities	POSTCODE				
	to consult with broader stakeholders – beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you need further clarification).	POSTCODE	Select if relevant	RATE HOW OFTEN YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT 3 = ALWAYS		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	POSTCODE I don't know – I am not aware		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 			YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs Groups already established in the area		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs Groups already established in the area Call in Radio Shows /		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs Groups already established in the area Call in Radio Shows / News Press TV Media Theatre/Music/Sport events		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs Groups already established in the area Call in Radio Shows / News Press TV Media		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		
	 beyond the immediate communities where the trial is underway?(refer to diagram at the start of interview if you 	I don't know – I am not aware Broader Stakeholder Advisory Meetings Local Events Ongoing dialogue with NGOs or CBOs Political Groups NGO Advisory Groups Social Cultural Groups Professional Groups CABs Groups already established in the area Call in Radio Shows / News Press TV Media Theatre/Music/Sport events		YOU DO THIS 0 = NEVER 1 = OCCASIONAL 2 = FREQUENT		

D2 - 1.12		1 year which community or broader the following activities relating to th		CSH	BSH	None/ Neither/ Don't Know	
	Formative research activities – disc	cussions before the research begins					
	Stakeholder advisory plans – discussions to plan how all stakeholders and gate keepers are engaged in the study						
	Stakeholder education plan – discu community and broader stakeholders	ssions to plan how to sensitize and infor (as per definition at start)	m				
	Communication plans – discussion of communities for trial recruitment and	on how to communicate and reach out t enrolment.	o target				
	Issues management plan – discussion on how to address problems that may the community in relation to the research study						
	Site selection – discussion around w	hich research sites to select and why					
	Protocol development – discussion approach	plan and					
	Informed consent process - discus forms for prospective trial participants	sion around the informed consent proce	ss and				
	Access to care and treatment for tr trial participants may or may not recei	at services					
	Recruitment and retention and follow up – discussion about how to access, retain and support trial participants						
	Trial participant exit from trial - discussion on how to transition participants out of the trial when the trial ends						
	Results dissemination - discussion on research results and how to inform the community stakeholders						
	Post-trial access to care and treatmatter the research is complete	nent – discussion on services for trial p	articipants				
			S1	S2	S3	S4	
D2 - 1.13	In your assessment, over the past 6 months, how well is	Very well aligned – excellent					
	your engagement work on this	Aligned – good					
	trial aligned with GPP – good participatory practice guidelines?	Poorly aligned					
		Not aligned					
		I don't know – Not aware – What is GPP?					
D2 - 1.14	In your view what is the purpose of the Community Advisory Board or its equivalent in your institution – please provide as much detail as possible.						

D2 - 1.15 QUAL	Reflecting on the past 6 months what has been the predominant focus of your engagement with the community stakeholders (CSH) and broader stakeholders (BSH)?	Write your response	here			
		POSTCODE				
					CSH	BSH
		ADHERENCE ISSUES				
		COMMUNICATION PLA	AN			
		COMMUNITY ENTRY/	NTRO			
		CT/POST TRIAL ACCE	SS TO CARE			
		FOLLOW UP ISSUES				
		FORMATIVE WORK				
		INFORMED CONSENT				
		ISSUES MANAGEMEN				
		MOBILIZATION/SENS	TIZATION/EDUCATION	ON		
		PLANNING				
		POST TRIAL ACCESS	TO CARE			
		PROTOCOL DEVELOP	MENT			
		PROTOCOL REVIEW				
		RECRUITMENT				
		RESOURCE IDENTIFIC	CATION			
		RESULTS DISSEMINA	TION			
		RETENTION ISSUES				
		ROLE CLARIFICATION				
		SITE SELECTION				
		STAKEHOLDER ADVIS	ORY PLAN			
		STAKEHOLDER EDUC	ATION PLAN			
		STUDY BRIEFING				
		STUDY INFO UPDATE	S 			
		TRAINING				
		UPDATE/FEEDBACK				
		OTHER (specify)				
D2 - 1.16	Please write any key suggestions or any constructive solutions which you are aware the community stakeholders (can include the CAB), have made to any or all of your trials.	Write your response	here			
	מון טו מון טו ייטו נוומוט.	Did the trial act on these suggestions?	YES	NO	No suggest	ions made
D2 - 1.17	Please write any key suggestions or any constructive solutions which you are aware that any broader stakeholders have made to any or all of	Write your response	here			
	your trials.	Did the trial act on these suggestions?	YES	NO	No suggest	ions made
		uicoc ougycouviio!				

D2 - 1.18 QUAL	If you have acted on suggestions in the past 6 months, please share those actions in detail. If you have not acted on suggestions, can you explain why you think no actions have been taken, as a result of stakeholder participation?	Write your response				
D2 - 1.19	Based on results, over the past 6 months how important has your	Very Important and essential				
	stakeholder engagement programme been to the clinical trial operations?	Important but not essential				
	Soon to the chinese that operations.	Limited value				
		Not important				
		I don't know – there is no data to show value				
D2 - 1.20 QUAL	Please give concrete examples of how the stakeholder engagement programme has directly benefited the trial over the past 6 months? Note – do not make sweeping statements without concrete evidence.	Write your response				
D2 - 1.21	On average, over the past 6 months, how often have you consulted		CSH	BSH	NSH	ISH
	in person/directly with various stakeholders (SH)?	Every day				
	, ,	Every week at least once				
	CSH – community SH BSH – broader SH	Every month at least once				
	NSH – national SH ISH – international SH	Every 3 months at least once				
		At least twice a year				
		Once a year				
		Not sure – very rarely				
		Never				
D2 - 1.22	Reflecting on the past 6 months and thinking about results, are you very		CSH	BSH	NSH	ISH
	satisfied, satisfied, unsure, dissatisfied, very dissatisfied with your stakeholder	Very Satisfied				
	engagement outputs? (Abbreviations	Satisfied				
	as per previous question).	Unsure				
		Dissatisfied				
		Very Dissatisfied				
D2 - 1.23 QUAL	Elaborate on your answer above as to why you feel this way (very satisfied, satisfied, unsure, dissatisfied, or very dissatisfied) in relation to the different stakeholder engagement efforts undertaken by your trial. Please give a examples that illustrate your stand.	Write your response				

D2 - 1.24	Over the past 6 months, how would you rate the strength of your research		S1	S2	S3	S4
	projects' engagement with the stakeholders (for each of the trials underway	Very Strong The CSH or BSH is/are involved in all (90 - 100%) aspects of the research, from planning through dissemination of the research.				
	·	Strong The CSH or BSH is/are involved in most (71 - 89%) aspects of the research but not necessarily all development and planning.				
		Medium The CSH or BSH is/are involved in about 60 to 70% of the research process.				
		Weak The CSH or BSH is/are involved in very few aspects (40 - 59%) of the research activities				
		Very Weak The CSH or BSH is/are involved in less than 40 of the research activities				
		I don't know - Not in a position to judge				
D2 - 1.25 QUAL	In your opinion why does your research engage with community stakeholders (CSH)	Write your response here				
	broader stakeholders (BSH) national stakeholders (NSH) international stakeholders (ISH)	In your opinion why does your research engage				
		In your opinion why does your research engage	with bro	ader stal	keholder	s?
		In your opinion why does your research engage	with nati	onal sta	keholder	s?
		In your opinion why does your research engage	with inte	rnationa	l stakeho	olders?
		POSTCODE OPTIONS – YOU MAY CHOOSE UP TO	3 FOR E	ACH CAT	regory (OF SH
			CSH	BSH	NSH	ISH
		TO GET THE PERMISSIONS NECESSARY TO CONDUCT THE STUDY				
		TO ENHANCE RECRUITMENT AND RETENTION of trial participants				
		TO CONSULT WITH THEM – to gather their opinions/ideas/suggestions on the protocol, informed consent and other processes				
		TO SEEK THEIR APPROVAL – to facilitate/enable the research				
		TO CREATE AWARENESS – to prevent rumours and resistance in the community				
		TO LISTEN TO THE COMMUNITY & GATHER FEEDBACK on how the study is being received in the community				
		TO BUILD TRUST BETWEEN THE				
		STAKEHOLDERS AND THE RESEARCH – to enable future research				
		- to enable future research TO MITIGATE POTENTIAL CONTROVERSY - that				
		to enable future research TO MITIGATE POTENTIAL CONTROVERSY - that may interfere with the research TO PROTECT THE COMMUNITY - from research that is detrimental to the community TO DISCUSS POLICY & POST TRIAL IMPLEMENTATION				
		- to enable future research TO MITIGATE POTENTIAL CONTROVERSY - that may interfere with the research TO PROTECT THE COMMUNITY - from research that is detrimental to the community TO DISCUSS POLICY & POST TRIAL IMPLEMENTATION TO SEEK FUNDING AND CONTINUED SUPPORT				
		to enable future research TO MITIGATE POTENTIAL CONTROVERSY - that may interfere with the research TO PROTECT THE COMMUNITY - from research that is detrimental to the community TO DISCUSS POLICY & POST TRIAL IMPLEMENTATION				

D2 - 1.26	Reflecting on the past 6 months which of the following statements best represent your opinion? You may	th of the following statements represent your opinion? You may the success of the trial.				
	cnoose up to two options.	Community Stakeholder & Broader Stakeholder Enment is a waste of time, staff and finances – in redoes not contribute to the success of the trial.				
	Community Stakeholder & Broader Stakeholder Engag ment is valuable in theory, but in reality there is no day show us that it has a true benefit.					
		Community Stakeholder & Broader Stakeholder Enment is very important and the trial could not advisible without it.				
		Community Stakeholder & Broader Stakeholder En ment is an ethical requirement and clinical resear responsibility to engage with all levels of stakehol regardless of its impact on trial outcomes.				
D2 - 1.27	Do you think that your trial invests		TIME	STAFF	FINANCE	
	sufficient time, staff and finances into community and broader stakeholder	YES				
	engagement?	NO				
D2 - 1.28	In your opinion, over the past 6 months, how much value have your community	Great value				
	and broader stakeholder engagement	Some Value				
efforts added to your research study?		Questionable/Undetermined value				
		No value				
		I don't know – Not in a position to judge				
D2 - 1.29	TIME INTERVIEW ENDED	HOUR MINUTE				
PLEASE ATTACH ANY D	OCUMENTS THAT COULD SUPPORT YOUR I	RESPONSES				